<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37566027</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>15</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Studies of Genetic and Proteomic Risk Factors of Amyotrophic Lateral Sclerosis Inspire Biomarker Development and Gene Therapy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1948</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12151948</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease affecting the upper and lower motor neurons, leading to muscle weakness, motor impairments, disabilities and death. Approximately 5-10% of ALS cases are associated with positive family history (familial ALS or fALS), whilst the remainder are sporadic (sporadic ALS, sALS). At least 50 genes have been identified as causative or risk factors for ALS. Established pathogenic variants include superoxide dismutase type 1 (<i>SOD1</i>), chromosome 9 open reading frame 72 (<i>c9orf72</i>), TAR DNA Binding Protein (<i>TARDBP</i>), and Fused In Sarcoma (<i>FUS</i>); additional ALS-related genes including Charged Multivesicular Body Protein 2B (<i>CHMP2B</i>), Senataxin (<i>SETX</i>), Sequestosome 1 (<i>SQSTM1</i>), TANK Binding Kinase 1 (<i>TBK1</i>) and NIMA Related Kinase 1 (<i>NEK1</i>), have been identified. Mutations in these genes could impair different mechanisms, including vesicle transport, autophagy, and cytoskeletal or mitochondrial functions. So far, there is no effective therapy against ALS. Thus, early diagnosis and disease risk predictions remain one of the best options against ALS symptomologies. Proteomic biomarkers, microRNAs, and extracellular vehicles (EVs) serve as promising tools for disease diagnosis or progression assessment. These markers are relatively easy to obtain from blood or cerebrospinal fluids and can be used to identify potential genetic causative and risk factors even in the preclinical stage before symptoms appear. In addition, antisense oligonucleotides and RNA gene therapies have successfully been employed against other diseases, such as childhood-onset spinal muscular atrophy (SMA), which could also give hope to ALS patients. Therefore, an effective gene and biomarker panel should be generated for potentially "at risk" individuals to provide timely interventions and better treatment outcomes for ALS patients as soon as possible.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bagyinszky</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Graduate School of Environment Department of Industrial and Environmental Engineering, Gachon University, Seongnam-si 13120, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hulme</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5035-1488</Identifier><AffiliationInfo><Affiliation>Graduate School of Environment Department of Industrial and Environmental Engineering, Gachon University, Seongnam-si 13120, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Seong Soo A</ForeName><Initials>SSA</Initials><AffiliationInfo><Affiliation>Department of Bionano Technology, Gachon University, Seongnam-si 13120, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C484368">SETX protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber><NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D020365">RNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064251">Multifunctional Enzymes</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020365" MajorTopicYN="N">RNA Helicases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064251" MajorTopicYN="N">Multifunctional Enzymes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">genetic factors</Keyword><Keyword MajorTopicYN="N">proteomic markers</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37566027</ArticleId><ArticleId IdType="pmc">PMC10417729</ArticleId><ArticleId IdType="doi">10.3390/cells12151948</ArticleId><ArticleId IdType="pii">cells12151948</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulisz D. Amyotrophic lateral sclerosis: Disease state overview. Am. J. Manag. Care. 2018;24((Suppl. S15)):S320&#x2013;S326.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J.M., La Spada A.R. ALS motor phenotype heterogeneity, focality, and spread: Deconstructing motor neuron degeneration. Neurology. 2009;73:805&#x2013;811. doi: 10.1212/WNL.0b013e3181b6bbbd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181b6bbbd</ArticleId><ArticleId IdType="pmc">PMC2739608</ArticleId><ArticleId IdType="pubmed">19738176</ArticleId></ArticleIdList></Reference><Reference><Citation>Testa D., Lovati R., Ferrarini M., Salmoiraghi F., Filippini G. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2004;5:208&#x2013;212. doi: 10.1080/14660820410021311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820410021311</ArticleId><ArticleId IdType="pubmed">15799548</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G., Traynor B.J., Hardiman O., Chi&#xf2; A., Mitchell D., Swingler R.J., Millul A., Benn E., Beghi E., Eurals F. Incidence of amyotrophic lateral sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry. 2010;81:385&#x2013;390. doi: 10.1136/jnnp.2009.183525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Logroscino G., Hardiman O., Swingler R., Mitchell D., Beghi E., Traynor B. Eurals Consortium Prognostic factors in ALS: A critical review. Amyotroph. Lateral Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhout R., Verstraete E., Heuvel M.P.V.D., Veldink J.H., Berg L.H.V.D. Patterns of symptom development in patients with motor neuron disease. Amyotroph. Lateral Scler. Front. Degener. 2018;19:21&#x2013;28. doi: 10.1080/21678421.2017.1386688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1386688</ArticleId><ArticleId IdType="pubmed">29037065</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell J.R., Kiernan M.C., Vucic S., Hodges J.R. Motor neuron dysfunction in frontotemporal dementia. Brain. 2011;134:2582&#x2013;2594. doi: 10.1093/brain/awr195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr195</ArticleId><ArticleId IdType="pubmed">21840887</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon Y.A., Fratta P., Traynor B.J., Chia R. The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Front. Neurosci. 2020;14:42. doi: 10.3389/fnins.2020.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00042</ArticleId><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M., Brown R.H., Jr. Genetics of Amyotrophic Lateral Sclerosis. Cold Spring Harb. Perspect. Med. 2018;8:a024125. doi: 10.1101/cshperspect.a024125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024125</ArticleId><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch C.M., Wen N., Fan C.C., Yokoyama J.S., Kouri N., Ross O., H&#xf6;glinger G., M&#xfc;ller U., Ferrari R., Hardy J., et al. Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum. JAMA Neurol. 2018;75:860&#x2013;875. doi: 10.1001/jamaneurol.2018.0372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0372</ArticleId><ArticleId IdType="pmc">PMC6043387</ArticleId><ArticleId IdType="pubmed">29630712</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F., Ingre C., Roos P.M., Kamel F., Piehl F. Risk factors for amyotrophic lateral sclerosis. Clin. Epidemiology. 2015;7:181&#x2013;193. doi: 10.2147/CLEP.S37505.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S37505</ArticleId><ArticleId IdType="pmc">PMC4334292</ArticleId><ArticleId IdType="pubmed">25709501</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernyshova K., Inoue K., Yamashita S.-I., Fukuchi T., Kanki T. Glaucoma-Associated Mutations in the Optineurin Gene Have Limited Impact on Parkin-Dependent Mitophagy. Investig. Opthalmology Vis. Sci. 2019;60:3625&#x2013;3635. doi: 10.1167/iovs.19-27184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.19-27184</ArticleId><ArticleId IdType="pubmed">31469402</ArticleId></ArticleIdList></Reference><Reference><Citation>Nekoua M.P., Mercier A., Alhazmi A., Sane F., Alidjinou E.K., Hober D. Fighting Enteroviral Infections to Prevent Type 1 Diabetes. Microorganisms. 2022;10:768. doi: 10.3390/microorganisms10040768.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms10040768</ArticleId><ArticleId IdType="pmc">PMC9031364</ArticleId><ArticleId IdType="pubmed">35456818</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A.K., Kapoor V., Thotala D., Hallahan D.E. TAF15 contributes to the radiation-inducible stress response in cancer. Oncotarget. 2020;11:2647&#x2013;2659. doi: 10.18632/oncotarget.27663.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.27663</ArticleId><ArticleId IdType="pmc">PMC7343639</ArticleId><ArticleId IdType="pubmed">32676166</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao L., Cen J., Pan J., Liu D., Wang Y., Chen Z., Ruan C., Chen S. TAF15&#x2013;ZNF384 fusion gene in childhood mixed phenotype acute leukemia. Cancer Genet. 2017;211:1&#x2013;4. doi: 10.1016/j.cancergen.2016.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cancergen.2016.12.002</ArticleId><ArticleId IdType="pubmed">28279306</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman J.M., Fernando S.M., Grad L.I., Hill A.F., Turner B.J., Yerbury J.J., Cashman N.R. Disease Mechanisms in ALS: Misfolded SOD1 Transferred through Exosome-Dependent and Exosome-Independent Pathways. Cell. Mol. Neurobiol. 2016;36:377&#x2013;381. doi: 10.1007/s10571-015-0294-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-015-0294-3</ArticleId><ArticleId IdType="pubmed">26908139</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur S.J., McKeown S.R., Rashid S. Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis. Gene. 2016;577:109&#x2013;118. doi: 10.1016/j.gene.2015.11.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2015.11.049</ArticleId><ArticleId IdType="pubmed">26657039</ArticleId></ArticleIdList></Reference><Reference><Citation>Huai J., Zhang Z. Structural Properties and Interaction Partners of Familial ALS-Associated SOD1 Mutants. Front. Neurol. 2019;10:527. doi: 10.3389/fneur.2019.00527.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00527</ArticleId><ArticleId IdType="pmc">PMC6536575</ArticleId><ArticleId IdType="pubmed">31164862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace M.A., Liou L.L., Martins J., Clement M.H., Bailey S., Longo V.D., Valentine J.S., Gralla E.B. Superoxide inhibits 4Fe-4S cluster enzymes involved in amino acid biosynthesis. Cross-compartment protection by CuZn-superoxide dismutase. J. Biol. Chem. 2004;279:32055&#x2013;32062. doi: 10.1074/jbc.M403590200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M403590200</ArticleId><ArticleId IdType="pubmed">15166213</ArticleId></ArticleIdList></Reference><Reference><Citation>De Souza P.V.S., Pinto W.B.V.R., Farias I.B., Badia B.M.L., Pinto I.F.N., Costa G.C., Marin C.M., Dos Santos Jorge A.C., Souto E.C., Serrano P.L., et al. Progressive spastic tetraplegia and axial hypotonia (STAHP) due to SOD1 deficiency: Is it really a new entity? Orphanet J. Rare Dis. 2021;16:360. doi: 10.1186/s13023-021-01993-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-021-01993-0</ArticleId><ArticleId IdType="pmc">PMC8359534</ArticleId><ArticleId IdType="pubmed">34380534</ArticleId></ArticleIdList></Reference><Reference><Citation>Orrell R.W. Amyotrophic lateral sclerosis: Copper/zinc superoxide dismutase (SOD1) gene mutations. Neuromuscul. Disord. 2000;10:63&#x2013;68. doi: 10.1016/S0960-8966(99)00071-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-8966(99)00071-1</ArticleId><ArticleId IdType="pubmed">10677867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L.-Q., Ma Y., Yuan H.-Y., Zhao K., Zhang M.-Y., Wang Q., Huang X., Xu W.-C., Dai B., Chen J., et al. Cryo-EM structure of an amyloid fibril formed by full-length human SOD1 reveals its conformational conversion. Nat. Commun. 2022;13:3491. doi: 10.1038/s41467-022-31240-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31240-4</ArticleId><ArticleId IdType="pmc">PMC9205981</ArticleId><ArticleId IdType="pubmed">35715417</ArticleId></ArticleIdList></Reference><Reference><Citation>Broom H.R., Rumfeldt J.A.O., Vassall K.A., Meiering E.M. Destabilization of the dimer interface is a common consequence of diverse ALS-associated mutations in metal free SOD1. Protein Sci. 2015;24:2081&#x2013;2089. doi: 10.1002/pro.2803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.2803</ArticleId><ArticleId IdType="pmc">PMC4815230</ArticleId><ArticleId IdType="pubmed">26362407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Valdmanis P.N., Dion P., Rouleau G.A. Oxidized/misfolded superoxide dismutase-1: The cause of all amyotrophic lateral sclerosis? Ann. Neurol. 2007;62:553&#x2013;559. doi: 10.1002/ana.21319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21319</ArticleId><ArticleId IdType="pubmed">18074357</ArticleId></ArticleIdList></Reference><Reference><Citation>Peggion C., Scalcon V., Massimino M.L., Nies K., Lopreiato R., Rigobello M.P., Bertoli A. SOD1 in ALS: Taking Stock in Pathogenic Mechanisms and the Role of Glial and Muscle Cells. Antioxidants. 2022;11:614. doi: 10.3390/antiox11040614.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox11040614</ArticleId><ArticleId IdType="pmc">PMC9032988</ArticleId><ArticleId IdType="pubmed">35453299</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed M., Yang Y., Deng H.-X., Hung W.-Y., Siddique N., Dellefave L., Gellera C., Andersen P.M., Siddique T. Age and founder effect of SOD1 A4V mutation causing ALS. Neurology. 2009;72:1634&#x2013;1639. doi: 10.1212/01.wnl.0000343509.76828.2a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000343509.76828.2a</ArticleId><ArticleId IdType="pmc">PMC2683645</ArticleId><ArticleId IdType="pubmed">19176896</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine J.S., Hart P.J. Misfolded CuZnSOD and amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2003;100:3617&#x2013;3622. doi: 10.1073/pnas.0730423100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0730423100</ArticleId><ArticleId IdType="pmc">PMC152971</ArticleId><ArticleId IdType="pubmed">12655070</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z., Liu M.-S., Li X.-G., Cui L.-Y. H46R SOD1 mutation is consistently associated with a relatively benign form of amyotrophic lateral sclerosis with slow progression. Amyotroph. Lateral Scler. Front. Degener. 2016;17:610&#x2013;613. doi: 10.1080/21678421.2016.1199698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1199698</ArticleId><ArticleId IdType="pubmed">27348463</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm&#xf8;y T., Bj&#xf8;rgo K., Roos P.M. Slowly Progressing Amyotrophic Lateral Sclerosis Caused by H46R SOD1 Mutation. Eur. Neurol. 2007;58:57&#x2013;58. doi: 10.1159/000102170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000102170</ArticleId><ArticleId IdType="pubmed">17483589</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonyuk S., Elam J.S., Hough M.A., Strange R.W., Doucette P.A., Rodriguez J.A., Hayward L.J., Valentine J.S., Hart P.J., Hasnain S.S. Structural consequences of the familial amyotrophic lateral sclerosis SOD1 mutant His46Arg. Protein Sci. 2005;14:1201&#x2013;1213. doi: 10.1110/ps.041256705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1110/ps.041256705</ArticleId><ArticleId IdType="pmc">PMC2253262</ArticleId><ArticleId IdType="pubmed">15840828</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreilaus F., Guerra S., Masanetz R., Menne V., Yerbury J., Karl T. Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1G93A) mouse model of amyotrophic lateral sclerosis include sex-dependent phenotypes. Genes Brain Behav. 2020;19:e12604. doi: 10.1111/gbb.12604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/gbb.12604</ArticleId><ArticleId IdType="pubmed">31412164</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K., Mhatre M., Mou S., Pye Q.N., Stewart C., West M., Williamson K.S. On the relation of oxidative stress to neuroinflammation: Lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid. Redox Signal. 2006;8:2075&#x2013;2087. doi: 10.1089/ars.2006.8.2075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2006.8.2075</ArticleId><ArticleId IdType="pubmed">17034351</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton C.F., Cenik B., Cenik B.K., Herz J., Yu G. TDP-43 in central nervous system development and function: Clues to TDP-43-associated neurodegeneration. Biol. Chem. 2012;393:589&#x2013;594. doi: 10.1515/hsz-2012-0115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/hsz-2012-0115</ArticleId><ArticleId IdType="pmc">PMC3537500</ArticleId><ArticleId IdType="pubmed">22944662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo M., Lee S., Jeon Y.-M., Kim S., Kwon Y., Kim H.-J. The role of TDP-43 propagation in neurodegenerative diseases: Integrating insights from clinical and experimental studies. Exp. Mol. Med. 2020;52:1652&#x2013;1662. doi: 10.1038/s12276-020-00513-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-020-00513-7</ArticleId><ArticleId IdType="pmc">PMC8080625</ArticleId><ArticleId IdType="pubmed">33051572</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng C., Trojanowski J.Q., Lee V.M.-Y. Protein transmission in neurodegenerative disease. Nat. Rev. Neurol. 2020;16:199&#x2013;212. doi: 10.1038/s41582-020-0333-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0333-7</ArticleId><ArticleId IdType="pmc">PMC9242841</ArticleId><ArticleId IdType="pubmed">32203399</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., Baralle F.E. TDP-43: Gumming up neurons through protein-protein and protein-RNA interactions. Trends Biochem. Sci. 2012;37:237&#x2013;247. doi: 10.1016/j.tibs.2012.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2012.03.003</ArticleId><ArticleId IdType="pubmed">22534659</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Deng J., Dong J., Liu J., Bigio E.H., Mesulam M., Wang T., Sun L., Wang L., Lee A.Y.-L., et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 2019;15:e1007947. doi: 10.1371/journal.pgen.1007947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007947</ArticleId><ArticleId IdType="pmc">PMC6524796</ArticleId><ArticleId IdType="pubmed">31100073</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L., Ngo S.T. Altered TDP-43 Structure and Function: Key Insights into Aberrant RNA, Mitochondrial, and Cellular and Systemic Metabolism in Amyotrophic Lateral Sclerosis. Metabolites. 2022;12:709. doi: 10.3390/metabo12080709.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo12080709</ArticleId><ArticleId IdType="pmc">PMC9415507</ArticleId><ArticleId IdType="pubmed">36005581</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Li C., Shan J., Wang Y., Chen G. Insights into the aggregation mechanism of RNA recognition motif domains in TDP-43: A theoretical exploration. R. Soc. Open Sci. 2021;8:210160. doi: 10.1098/rsos.210160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsos.210160</ArticleId><ArticleId IdType="pmc">PMC8371369</ArticleId><ArticleId IdType="pubmed">34457335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim L., Wei Y., Lu Y., Song J. ALS-Causing Mutations Significantly Perturb the Self-Assembly and Interaction with Nucleic Acid of the Intrinsically Disordered Prion-Like Domain of TDP-43. PLoS Biol. 2016;14:e1002338. doi: 10.1371/journal.pbio.1002338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1002338</ArticleId><ArticleId IdType="pmc">PMC4703307</ArticleId><ArticleId IdType="pubmed">26735904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan R.H., Ke Y.D., Ittner L.M., Halliday G.M. ALS/FTLD: Experimental models and reality. Acta Neuropathol. 2017;133:177&#x2013;196. doi: 10.1007/s00401-016-1666-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1666-6</ArticleId><ArticleId IdType="pubmed">28058507</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.S., Snead D., Lee J.J., McCaffery J.M., Shorter J., Gitler A.D. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 2009;284:20329&#x2013;20339. doi: 10.1074/jbc.M109.010264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.010264</ArticleId><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuzawa S., Akiyama T., Nishiyama A., Suzuki N., Kato M., Warita H., Izumi R., Osana S., Koyama S., Kato T., et al. TARDBP p.G376D mutation, found in rapid progressive familial ALS, induces mislocalization of TDP-43. Eneurologicalsci. 2018;11:20&#x2013;22. doi: 10.1016/j.ensci.2018.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.04.001</ArticleId><ArticleId IdType="pmc">PMC6006914</ArticleId><ArticleId IdType="pubmed">29928714</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S., Rouleau G.A., Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: Summary and update. Hum. Mutat. 2013;34:812&#x2013;826. doi: 10.1002/humu.22319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22319</ArticleId><ArticleId IdType="pubmed">23559573</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesiridis G.S., Lee V.M.-Y., Trojanowski J.Q. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum. Mol. Genet. 2009;18:R156&#x2013;R162. doi: 10.1093/hmg/ddp303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp303</ArticleId><ArticleId IdType="pmc">PMC2758707</ArticleId><ArticleId IdType="pubmed">19808791</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Ding X., Akram N., Xue S., Luo S.-Z. Fused in Sarcoma: Properties, Self-Assembly and Correlation with Neurodegenerative Diseases. Molecules. 2019;24:1622. doi: 10.3390/molecules24081622.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24081622</ArticleId><ArticleId IdType="pmc">PMC6514960</ArticleId><ArticleId IdType="pubmed">31022909</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho W.Y., Agrawal I., Tyan S.-H., Sanford E., Chang W.-T., Lim K., Ong J., Tan B.S.Y., Moe A.A.K., Yu R., et al. Dysfunction in nonsense-mediated decay, protein homeostasis, mitochondrial function, and brain connectivity in ALS-FUS mice with cognitive deficits. Acta Neuropathol. Commun. 2021;9:9. doi: 10.1186/s40478-020-01111-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-01111-4</ArticleId><ArticleId IdType="pmc">PMC7789430</ArticleId><ArticleId IdType="pubmed">33407930</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H., Gao K., Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat. Rev. Neurol. 2014;10:337&#x2013;348. doi: 10.1038/nrneurol.2014.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.78</ArticleId><ArticleId IdType="pubmed">24840975</ArticleId></ArticleIdList></Reference><Reference><Citation>An H., Skelt L., Notaro A., Highley J.R., Fox A.H., La Bella V., Buchman V.L., Shelkovnikova T.A. ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles. Acta Neuropathol. Commun. 2019;7:7. doi: 10.1186/s40478-019-0658-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0658-x</ArticleId><ArticleId IdType="pmc">PMC6330737</ArticleId><ArticleId IdType="pubmed">30642400</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang Y., Huang E.J. Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis. Brain Res. 2016;1647:65&#x2013;78. doi: 10.1016/j.brainres.2016.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.03.036</ArticleId><ArticleId IdType="pmc">PMC5003642</ArticleId><ArticleId IdType="pubmed">27033831</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter E.L., Chen H.-J., Shaw C.E. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics. 2015;12:352&#x2013;363. doi: 10.1007/s13311-015-0338-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0338-x</ArticleId><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>Sama R.R.K., Fallini C., Gatto R., McKeon J.E., Song Y., Rotunno M.S., Penaranda S., Abdurakhmanov I., Landers J.E., Morfini G., et al. ALS-linked FUS exerts a gain of toxic function involving aberrant p38 MAPK activation. Sci. Rep. 2017;7:115. doi: 10.1038/s41598-017-00091-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-00091-1</ArticleId><ArticleId IdType="pmc">PMC5428330</ArticleId><ArticleId IdType="pubmed">28273913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Liu S., Liu G., &#xd6;zt&#xfc;rk A., Hicks G.G. ALS-associated FUS mutations result in compromised FUS alternative splicing and autoregulation. PLoS Genet. 2013;9:e1003895. doi: 10.1371/journal.pgen.1003895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1003895</ArticleId><ArticleId IdType="pmc">PMC3814325</ArticleId><ArticleId IdType="pubmed">24204307</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamelgarn M., Chen J., Kuang L., Jin H., Kasarskis E.J., Zhu H. ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay. Proc. Natl. Acad. Sci. USA. 2018;115:E11904&#x2013;E11913. doi: 10.1073/pnas.1810413115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1810413115</ArticleId><ArticleId IdType="pmc">PMC6304956</ArticleId><ArticleId IdType="pubmed">30455313</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Rademakers R., Roeber S., Baker M., Kretzschmar H.A., Mackenzie I.R.A. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132:2922&#x2013;2931. doi: 10.1093/brain/awp214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp214</ArticleId><ArticleId IdType="pmc">PMC2768659</ArticleId><ArticleId IdType="pubmed">19674978</ArticleId></ArticleIdList></Reference><Reference><Citation>King O.D., Gitler A.D., Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012;1462:61&#x2013;80. doi: 10.1016/j.brainres.2012.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.01.016</ArticleId><ArticleId IdType="pmc">PMC3372647</ArticleId><ArticleId IdType="pubmed">22445064</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya T., Maragkakis M. Amyotrophic Lateral Sclerosis associated FUS mutation shortens mitochondria and induces neurotoxicity. Sci. Rep. 2018;8:15575. doi: 10.1038/s41598-018-33964-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-33964-0</ArticleId><ArticleId IdType="pmc">PMC6197261</ArticleId><ArticleId IdType="pubmed">30349096</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M., Zhao X., Wu W., Wang Q., Liu J., Zhang W., Yuan Y., Hong D., Wang Z., Deng J. Widespread Mislocalization of FUS Is Associated with Mitochondrial Abnormalities in Skeletal Muscle in Amyotrophic Lateral Sclerosis With FUS Mutations. J. Neuropathol. Exp. Neurol. 2022;81:172&#x2013;181. doi: 10.1093/jnen/nlac004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlac004</ArticleId><ArticleId IdType="pubmed">35139534</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeyers J., Banchi E.G., Latouche M. C9ORF72: What It Is, What It Does, and Why It Matters. Front Cell Neurosci. 2021;15:661447. doi: 10.3389/fncel.2021.661447.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.661447</ArticleId><ArticleId IdType="pmc">PMC8131521</ArticleId><ArticleId IdType="pubmed">34025358</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Sim&#xf3;n-S&#xe1;nchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I., Van Mossevelde S., van der Zee J., Sieben A., Engelborghs S., De Bleecker J., Ivanoiu A., Deryck O., Edbauer D., Zhang M., et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Mol. Psychiatry. 2015;21:1112&#x2013;1124. doi: 10.1038/mp.2015.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.159</ArticleId><ArticleId IdType="pmc">PMC4960451</ArticleId><ArticleId IdType="pubmed">26481318</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Zee J., Gijselinck I., Dillen L., Van Langenhove T., Theuns J., Engelborghs S., Philtjens S., Vandenbulcke M., Sleegers K., Sieben A., et al. European Early-Onset Dementia Consortium. A pan-European study of the C9orf72 repeat associated with FTLD: Geographic prevalence, genomic instability, and intermediate repeats. Hum. Mutat. 2013;34:363&#x2013;373. doi: 10.1002/humu.22244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22244</ArticleId><ArticleId IdType="pmc">PMC3638346</ArticleId><ArticleId IdType="pubmed">23111906</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers M., Blokhuis A.M., Westeneng H., Terpstra M.L., Zundel C.A.C., de S&#xe1; R.V., Schellevis R.D., Waite A.J., Blake D.J., Veldink J.H., et al. C 9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann. Neurol. 2015;78:426&#x2013;438. doi: 10.1002/ana.24453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24453</ArticleId><ArticleId IdType="pmc">PMC4744979</ArticleId><ArticleId IdType="pubmed">26044557</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Weng S.-M., Arzberger T., May S., Rentzsch K., Kremmer E., Schmid B., Kretzschmar H.A., Cruts M., Van Broeckhoven C., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338. doi: 10.1126/science.1232927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaegebeur A., Glaria I., Lashley T., Isaacs A.M. Soluble and insoluble dipeptide repeat protein measurements in C9orf72-frontotemporal dementia brains show regional differential solubility and correlation of poly-GR with clinical severity. Acta Neuropathol. Commun. 2020;8:184. doi: 10.1186/s40478-020-01036-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-01036-y</ArticleId><ArticleId IdType="pmc">PMC7650212</ArticleId><ArticleId IdType="pubmed">33168090</ArticleId></ArticleIdList></Reference><Reference><Citation>May S., Hornburg D., Schludi M.H., Arzberger T., Rentzsch K., Schwenk B.M., Gr&#xe4;sser F.A., Mori K., Kremmer E., Banzhaf-Strathmann J., et al. C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol. 2014;128:485&#x2013;503. doi: 10.1007/s00401-014-1329-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1329-4</ArticleId><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., Gr&#xf6;nke S., Niccoli T., Ridler C.E., Clayton E.L., Devoy A., Moens T., Norona F.E., Woollacott I.O.C., Pietrzyk J., et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194. doi: 10.1126/science.1256800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1256800</ArticleId><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler A.R., Donnelly C.J., Rothstein J.D. The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nat. Rev. Neurosci. 2016;17:383&#x2013;395. doi: 10.1038/nrn.2016.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.38</ArticleId><ArticleId IdType="pmc">PMC7376590</ArticleId><ArticleId IdType="pubmed">27150398</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitiprolu M., Jagow C., Tremblay V., Bondy-Chorney E., Paris G., Savard A., Palidwor G., Barry F.A., Zinman L., Keith J., et al. A complex of C9ORF72 and p62 uses arginine methylation to eliminate stress granules by autophagy. Nat. Commun. 2018;9:2794. doi: 10.1038/s41467-018-05273-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05273-7</ArticleId><ArticleId IdType="pmc">PMC6052026</ArticleId><ArticleId IdType="pubmed">30022074</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker C., Herranz-Martin S., Karyka E., Liao C., Lewis K., Elsayed W., Lukashchuk V., Chiang S.-C., Ray S., Mulcahy P.J., et al. C9orf72 expansion disrupts ATM-mediated chromosomal break repair. Nat. Neurosci. 2017;20:1225&#x2013;1235. doi: 10.1038/nn.4604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4604</ArticleId><ArticleId IdType="pmc">PMC5578434</ArticleId><ArticleId IdType="pubmed">28714954</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead R.J., Shan N., Reiser H.J., Marshall F., Shaw P.J. Amyotrophic lateral sclerosis: A neurodegenerative disorder poised for successful therapeutic translation. Nat. Rev. Drug Discov. 2023;22:185&#x2013;212. doi: 10.1038/s41573-022-00612-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00612-2</ArticleId><ArticleId IdType="pmc">PMC9768794</ArticleId><ArticleId IdType="pubmed">36543887</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugbode C., West R.J. Lessons learned from CHMP2B, implications for frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol. Dis. 2021;147:105144. doi: 10.1016/j.nbd.2020.105144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105144</ArticleId><ArticleId IdType="pubmed">33144171</ArticleId></ArticleIdList></Reference><Reference><Citation>Babst M., Katzmann D.J., Estepa-Sabal E.J., Meerloo T., Emr S.D. Escrt-III: An endosome-associated heterooligomeric protein complex required for mvb sorting. Dev. Cell. 2002;3:271&#x2013;282. doi: 10.1016/S1534-5807(02)00220-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1534-5807(02)00220-4</ArticleId><ArticleId IdType="pubmed">12194857</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X., Sun X., Yue W., Duan Y., Hu R., Zhang K., Ni J., Cui J., Wang Q., Chen Y., et al. CHMP2B regulates TDP-43 phosphorylation and cytotoxicity independent of autophagy via CK1. J. Cell Biol. 2022;221:e202103033. doi: 10.1083/jcb.202103033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.202103033</ArticleId><ArticleId IdType="pmc">PMC8570292</ArticleId><ArticleId IdType="pubmed">34726688</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers M., van Blitterswijk M.M., Vlam L., Rowicka P.A., van Vught P.W., Groen E.J., Spliet W.G., Engelen-Lee J., Schelhaas H.J., de Visser M., et al. VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol. Aging. 2012;33:837.e7&#x2013;837.e13. doi: 10.1016/j.neurobiolaging.2011.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.006</ArticleId><ArticleId IdType="pubmed">22078486</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari V., Cristofani R., Tedesco B., Crippa V., Chierichetti M., Casarotto E., Cozzi M., Mina F., Piccolella M., Galbiati M., et al. Valosin Containing Protein (VCP): A Multistep Regulator of Autophagy. Int. J. Mol. Sci. 2022;23:1939. doi: 10.3390/ijms23041939.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23041939</ArticleId><ArticleId IdType="pmc">PMC8878954</ArticleId><ArticleId IdType="pubmed">35216053</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw C.E. Capturing VCP: Another Molecular Piece in the ALS Jigsaw Puzzle. Neuron. 2010;68:812&#x2013;814. doi: 10.1016/j.neuron.2010.11.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.040</ArticleId><ArticleId IdType="pubmed">21144996</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.O., Mandrioli J., Benatar M., Abramzon Y., Van Deerlin V.M., Trojanowski J.Q., Gibbs J.R., Brunetti M., Gronka S., Wuu J., et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857&#x2013;864. doi: 10.1016/j.neuron.2010.11.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.036</ArticleId><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadoni M.P.L., Biggio M.L., Arru G., Secchi G., Orr&#xf9; N., Clemente M.G., Sechi G., Yamoah A., Tripathi P., Orr&#xf9; S., et al. VAPB ER-Aggregates, A Possible New Biomarker in ALS Pathology. Cells. 2020;9:164. doi: 10.3390/cells9010164.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9010164</ArticleId><ArticleId IdType="pmc">PMC7017080</ArticleId><ArticleId IdType="pubmed">31936602</ArticleId></ArticleIdList></Reference><Reference><Citation>Landers J.E., Leclerc A.L., Shi L., Virkud A., Cho T., Maxwell M.M., Henry A.F., Polak M., Glass J.D., Kwiatkowski T.J., et al. New VAPB deletion variant and exclusion of VAPB mutations in familial ALS. Neurology. 2008;70:1179&#x2013;1185. doi: 10.1212/01.wnl.0000289760.85237.4e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000289760.85237.4e</ArticleId><ArticleId IdType="pubmed">18322265</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson G., Lenk G.M., Reddel S.W., Grant A.E., Towne C.F., Ferguson C.J., Simpson E., Scheuerle A., Yasick M., Hoffman S., et al. Distinctive genetic and clinical features of CMT4J: A severe neuropathy caused by mutations in the PI(3,5)P2 phosphatase FIG4. Brain. 2011;134:1959&#x2013;1971. doi: 10.1093/brain/awr148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr148</ArticleId><ArticleId IdType="pmc">PMC3122378</ArticleId><ArticleId IdType="pubmed">21705420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon T., Mori F., Tanji K., Miki Y., Toyoshima Y., Yoshida M., Sasaki H., Kakita A., Takahashi H., Wakabayashi K. ALS-associated protein FIG4 is localized in Pick and Lewy bodies, and also neuronal nuclear inclusions, in polyglutamine and intranuclear inclusion body diseases. Neuropathology. 2014;34:19&#x2013;26. doi: 10.1111/neup.12056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12056</ArticleId><ArticleId IdType="pubmed">23888880</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmanovic A., Rangnau I., Kosfeld A., Abdulla S., Janssen C., Auber B., Raab P., Preller M., Petri S., Weber R.G. FIG4 variants in central European patients with amyotrophic lateral sclerosis: A whole-exome and targeted sequencing study. Eur. J. Hum. Genet. 2017;25:324&#x2013;331. doi: 10.1038/ejhg.2016.186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2016.186</ArticleId><ArticleId IdType="pmc">PMC5315518</ArticleId><ArticleId IdType="pubmed">28051077</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertolin C., Querin G., Bozzoni V., Martinelli I., De Bortoli M., Rampazzo A., Gellera C., Pegoraro E., Sorar&#xf9; G. New FIG4 gene mutations causing aggressive ALS. Eur. J. Neurol. 2018;25:e41&#x2013;e42. doi: 10.1111/ene.13559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13559</ArticleId><ArticleId IdType="pubmed">29464931</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.-Y., Lin J.-L., Feng S.-Y., Che C.-H., Huang H.-P., Zou Z.-Y. Novel Variants in the FIG4 Gene Associated with Chinese Sporadic Amyotrophic Lateral Sclerosis with Slow Progression. J. Clin. Neurol. 2022;18:41&#x2013;47. doi: 10.3988/jcn.2022.18.1.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2022.18.1.41</ArticleId><ArticleId IdType="pmc">PMC8762508</ArticleId><ArticleId IdType="pubmed">35021275</ArticleId></ArticleIdList></Reference><Reference><Citation>Khani M., Shamshiri H., Fatehi F., Rohani M., Ashtiani B.H., Akhoundi F.H., Alavi A., Moazzeni H., Taheri H., Ghani M.T., et al. Description of combined ARHSP/JALS phenotype in some patients with SPG11 mutations. Mol. Genet. Genom. Med. 2020;8:e1240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7336765</ArticleId><ArticleId IdType="pubmed">32383541</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutry M., Pierga A., Matusiak R., Branchu J., Houllegatte M., Ibrahim Y., Balse E., El Hachimi K.-H., Brice A., Stevanin G., et al. Loss of spatacsin impairs cholesterol trafficking and calcium homeostasis. Commun. Biol. 2019;2:380. doi: 10.1038/s42003-019-0615-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-019-0615-z</ArticleId><ArticleId IdType="pmc">PMC6797781</ArticleId><ArticleId IdType="pubmed">31637311</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauw H.M., van Rheenen W., Koppers M., Van Damme P., Waibel S., Lemmens R., van Vught P.W.J., Meyer T., Schulte C., Gasser T., et al. NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. Hum. Mol. Genet. 2012;21:2497&#x2013;2502. doi: 10.1093/hmg/dds064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds064</ArticleId><ArticleId IdType="pubmed">22378146</ArticleId></ArticleIdList></Reference><Reference><Citation>Goytain A., Hines R.M., El-Husseini A., Quamme G.A. NIPA1(SPG6), the basis for autosomal dominant form of hereditary spastic paraplegia, encodes a functional Mg2+ transporter. J. Biol. Chem. 2007;282:8060&#x2013;8068. doi: 10.1074/jbc.M610314200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M610314200</ArticleId><ArticleId IdType="pubmed">17166836</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrado L., Brunetti M., Di Pierro A., Barberis M., Croce R., Bersano E., De Marchi F., Zuccal&#xe0; M., Barizzone N., Calvo A., et al. Analysis of the GCG repeat length in NIPA1 gene in C9orf72-mediated ALS in a large Italian ALS cohort. Neurol Sci. 2019;40:2537&#x2013;2540. doi: 10.1007/s10072-019-04001-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04001-3</ArticleId><ArticleId IdType="pubmed">31286297</ArticleId></ArticleIdList></Reference><Reference><Citation>Tazelaar G.H., Dekker A.M., van Vugt J.J., van der Spek R.A., Westeneng H.-J., Kool L.J., Kenna K.P., van Rheenen W., Pulit S.L., McLaughlin R.L., et al. Association of NIPA1 repeat expansions with amyotrophic lateral sclerosis in a large international cohort. Neurobiol. Aging. 2019;74:234.e9&#x2013;234.e15. doi: 10.1016/j.neurobiolaging.2018.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.09.012</ArticleId><ArticleId IdType="pmc">PMC7893598</ArticleId><ArticleId IdType="pubmed">30342764</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams K.L., Topp S., Yang S., Smith B., Fifita J.A., Warraich S.T., Zhang K.Y., Farrawell N., Vance C., Hu X., et al. CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat. Commun. 2016;7:11253. doi: 10.1038/ncomms11253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11253</ArticleId><ArticleId IdType="pmc">PMC4835537</ArticleId><ArticleId IdType="pubmed">27080313</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayner S.L., Hogan A., Davidson J.M., Cheng F., Luu L., Morsch M., Blair I., Chung R., Lee A. Cyclin F, Neurodegeneration, and the Pathogenesis of ALS/FTD. Neuroscientist. 2022;5:10738584221120182. doi: 10.1177/10738584221120182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10738584221120182</ArticleId><ArticleId IdType="pubmed">36062310</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrawell N.E., Bax M., McAlary L., McKenna J., Maksour S., Do-Ha D., Rayner S.L., Blair I.P., Chung R.S., Yerbury J.J., et al. ALS-linked CCNF variant disrupts motor neuron ubiquitin homeostasis. Hum. Mol. Genet. 2023;32:2386&#x2013;2398. doi: 10.1093/hmg/ddad063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddad063</ArticleId><ArticleId IdType="pubmed">37220877</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y., Nakagawa T., Morohoshi A., Nakagawa M., Ishida N., Suzuki N., Aoki M., Nakayama K. Pathogenic mutations in the ALS gene CCNF cause cytoplasmic mislocalization of Cyclin F and elevated VCP ATPase activity. Hum. Mol. Genet. 2019;28:3486&#x2013;3497. doi: 10.1093/hmg/ddz119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz119</ArticleId><ArticleId IdType="pubmed">31577344</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.-X., Chen W., Hong S.-T., Boycott K.M., Gorrie G.H., Siddique N., Yang Y., Fecto F., Shi Y., Zhai H., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477:211&#x2013;215. doi: 10.1038/nature10353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10353</ArticleId><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L., Monteiro M.J. Defective Proteasome Delivery of Polyubiquitinated Proteins by Ubiquilin-2 Proteins Containing ALS Mutations. PLoS ONE. 2015;10:e0130162. doi: 10.1371/journal.pone.0130162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0130162</ArticleId><ArticleId IdType="pmc">PMC4468220</ArticleId><ArticleId IdType="pubmed">26075709</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J.J., Cai A., Greenslade J.E., Higgins N.R., Fan C., Le N.T., Tatman M., Whiteley A.M., Prado M.A., Dieriks B.V., et al. ALS/FTD mutations in UBQLN2 impede autophagy by reducing autophagosome acidification through loss of function. Proc. Natl. Acad. Sci. USA. 2021;118:e2114051118. doi: 10.1073/pnas.1917371117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1917371117</ArticleId><ArticleId IdType="pmc">PMC7334651</ArticleId><ArticleId IdType="pubmed">32513711</ArticleId></ArticleIdList></Reference><Reference><Citation>Capponi S., Geuens T., Geroldi A., Origone P., Verdiani S., Cichero E., Adriaenssens E., De Winter V., di Poggio M.B., Barberis M., et al. Molecular Chaperones in the Pathogenesis of Amyotrophic Lateral Sclerosis: The Role of HSPB1. Hum. Mutat. 2016;37:1202&#x2013;1208. doi: 10.1002/humu.23062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23062</ArticleId><ArticleId IdType="pmc">PMC5108433</ArticleId><ArticleId IdType="pubmed">27492805</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilman P.L., Song S., Miranda C.J., Meyer K., Srivastava A.K., Knapp A., Wier C.G., Kaspar B.K., Kolb S.J. HSPB1 mutations causing hereditary neuropathy in humans disrupt non-cell autonomous protection of motor neurons. Exp. Neurol. 2017;297:101&#x2013;109. doi: 10.1016/j.expneurol.2017.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2017.08.002</ArticleId><ArticleId IdType="pmc">PMC5612892</ArticleId><ArticleId IdType="pubmed">28797631</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidar M., Asselbergh B., Adriaenssens E., De Winter V., Timmermans J.P., Auer-Grumbach M., Juneja M., Timmerman V. Neuropathy-causing mutations in HSPB1 impair autophagy by disturbing the formation of SQSTM1/p62 bodies. Autophagy. 2019;15:1051&#x2013;1068. doi: 10.1080/15548627.2019.1569930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2019.1569930</ArticleId><ArticleId IdType="pmc">PMC6526868</ArticleId><ArticleId IdType="pubmed">30669930</ArticleId></ArticleIdList></Reference><Reference><Citation>Dierick I., Irobi J., Janssens S., Theuns J., Lemmens R., Jacobs A., Corsmit E., Hersmus N., Van Den Bosch L., Robberecht W. Genetic variant in the HSPB1 promoter region impairs the HSP27 stress response. Hum Mutat. 2007 Aug;28(8):830. Hum Mutat. 2007;28:830. doi: 10.1002/humu.9503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.9503</ArticleId><ArticleId IdType="pubmed">17623484</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu M., Waguri S., Koike M., Sou Y.S., Ueno T., Hara T., Mizushima N., Iwata J., Ezaki J., Murata S., et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell. 2007;131:1149&#x2013;1163. doi: 10.1016/j.cell.2007.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.10.035</ArticleId><ArticleId IdType="pubmed">18083104</ArticleId></ArticleIdList></Reference><Reference><Citation>Goode A., Butler K., Long J., Cavey J., Scott D., Shaw B., Sollenberger J., Gell C., Johansen T., Oldham N.J., et al. Defective recognition of LC3B by mutant SQSTM1/p62 implicates impairment of autophagy as a pathogenic mechanism in ALS-FTLD. Autophagy. 2016;12:1094&#x2013;1104. doi: 10.1080/15548627.2016.1170257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2016.1170257</ArticleId><ArticleId IdType="pmc">PMC4990988</ArticleId><ArticleId IdType="pubmed">27158844</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Z., Lim J., Wang Q., Purtell K., Wu S., Palomo G.M., Tan H., Manfredi G., Zhao Y., Peng J., et al. ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway. Autophagy. 2020;16:917&#x2013;931. doi: 10.1080/15548627.2019.1644076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2019.1644076</ArticleId><ArticleId IdType="pmc">PMC7144840</ArticleId><ArticleId IdType="pubmed">31362587</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Zou Q., Xie X., Liu T., Li H.S., Jie Z., Jin J., Hu H., Manyam G., Zhang L., et al. The kinase TBK1 functions in dendritic cells to regulate T cell homeostasis, autoimmunity, and antitumor immunity. J. Exp. Med. 2017;214:1493&#x2013;1507. doi: 10.1084/jem.20161524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20161524</ArticleId><ArticleId IdType="pmc">PMC5413337</ArticleId><ArticleId IdType="pubmed">28356390</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding O., Evans C.S., Ye J., Cheung J., Maniatis T., Holzbaur E.L.F. ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy. Proc. Natl. Acad. Sci. USA. 2021;118:e2025053118. doi: 10.1073/pnas.2025053118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2025053118</ArticleId><ArticleId IdType="pmc">PMC8214690</ArticleId><ArticleId IdType="pubmed">34099552</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye J., Cheung J., Gerbino V., Ahls&#xe9;n G., Zimanyi C., Hirsh D., Maniatis T. Effects of ALS-associated TANK binding kinase 1 mutations on protein&#x2013;protein interactions and kinase activity. Proc. Natl. Acad. Sci. USA. 2019;116:24517&#x2013;24526. doi: 10.1073/pnas.1915732116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1915732116</ArticleId><ArticleId IdType="pmc">PMC6900539</ArticleId><ArticleId IdType="pubmed">31748271</ArticleId></ArticleIdList></Reference><Reference><Citation>Toth R.P., Atkin J.D. Dysfunction of Optineurin in Amyotrophic Lateral Sclerosis and Glaucoma. Front. Immunol. 2018;9:1017. doi: 10.3389/fimmu.2018.01017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01017</ArticleId><ArticleId IdType="pmc">PMC5974248</ArticleId><ArticleId IdType="pubmed">29875767</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild P., Farhan H., McEwan D.G., Wagner S., Rogov V.V., Brady N.R., Richter B., Korac J., Waidmann O., Choudhary C., et al. Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. Science. 2011;333:228&#x2013;233. doi: 10.1126/science.1205405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1205405</ArticleId><ArticleId IdType="pmc">PMC3714538</ArticleId><ArticleId IdType="pubmed">21617041</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter B., Sliter D.A., Herhaus L., Stolz A., Wang C., Beli P., Zaffagnini G., Wild P., Martens S., Wagner S.A., et al. Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria. Proc. Natl. Acad. Sci. USA. 2016;113:4039&#x2013;4044. doi: 10.1073/pnas.1523926113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1523926113</ArticleId><ArticleId IdType="pmc">PMC4839414</ArticleId><ArticleId IdType="pubmed">27035970</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Kang J., Horwitz M.S. Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains. Mol. Cell. Biol. 1998;18:1601&#x2013;1610. doi: 10.1128/MCB.18.3.1601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.18.3.1601</ArticleId><ArticleId IdType="pmc">PMC108875</ArticleId><ArticleId IdType="pubmed">9488477</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223&#x2013;226. doi: 10.1038/nature08971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayloo S., Lazarus J.E., Dodda A., Tokito M., Ostap E.M., Holzbaur E.L. Dynactin functions as both a dynamic tether and brake during dynein-driven motility. Nat. Commun. 2014;5:4807. doi: 10.1038/ncomms5807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5807</ArticleId><ArticleId IdType="pmc">PMC4470572</ArticleId><ArticleId IdType="pubmed">25185702</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilarino-Guell C., Wider C., Soto-Ortolaza A.I., Cobb S.A., Kachergus J.M., Keeling B.H., Dachsel J.C., Hulihan M.M., Dickson D.W., Wszolek Z.K., et al. Characterization of DCTN1 genetic variability in neurodegeneration. Neurology. 2009;72:2024&#x2013;2028. doi: 10.1212/WNL.0b013e3181a92c4c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181a92c4c</ArticleId><ArticleId IdType="pmc">PMC2692178</ArticleId><ArticleId IdType="pubmed">19506225</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshimaru M., Kinoshita-Kawada M., Kubota K., Watanabe T., Tanaka Y., Hirano S., Ishidate F., Hiramoto M., Ishikawa M., Uehara Y., et al. DCTN1 Binds to TDP-43 and Regulates TDP-43 Aggregation. Int. J. Mol. Sci. 2021;22:3985. doi: 10.3390/ijms22083985.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22083985</ArticleId><ArticleId IdType="pmc">PMC8070438</ArticleId><ArticleId IdType="pubmed">33924373</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiel C., Kessler K., Giessl A., Dimmler A., Shalev S.A., von der Haar S., Zenker M., Zahnleiter D., St&#xf6;ss H., Beinder E., et al. NEK1 mutations cause short-rib polydactyly syndrome type majewski. Am. J. Hum. Genet. 2011;88:106&#x2013;114. doi: 10.1016/j.ajhg.2010.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2010.12.004</ArticleId><ArticleId IdType="pmc">PMC3014367</ArticleId><ArticleId IdType="pubmed">21211617</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna K.P., van Doormaal P.T., Dekker A.M., Ticozzi N., Kenna B.J., Diekstra F.P., van Rheenen W., van Eijk K.R., Jones A.R., Keagle P., et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1037&#x2013;1042. doi: 10.1038/ng.3626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3626</ArticleId><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D., M&#xfc;ller K., Wieland T., Weydt P., B&#xf6;hm S., Lul&#xe9; D., H&#xfc;bers A., Neuwirth C., Weber M., Borck G., et al. NEK1 mutations in familial amyotrophic lateral sclerosis. Brain. 2016;139:e28. doi: 10.1093/brain/aww033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww033</ArticleId><ArticleId IdType="pubmed">26945885</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.-H., Fallini C., Ticozzi N., Keagle P.J., Sapp P.C., Piotrowska K., Lowe P., Koppers M., McKenna-Yasek D., Baron D.M., et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488:499&#x2013;503. doi: 10.1038/nature11280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11280</ArticleId><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Danielson E.W., Qiao T., Metterville J., Brown R.H., Jr., Landers J.E., Xu Z. Mutant PFN1 causes ALS phenotypes and progressive motor neuron degeneration in mice by a gain of toxicity. Proc. Natl. Acad. Sci. USA. 2016;113:E6209&#x2013;E6218. doi: 10.1073/pnas.1605964113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1605964113</ArticleId><ArticleId IdType="pmc">PMC5068285</ArticleId><ArticleId IdType="pubmed">27681617</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt E.J., Funes S., McKeon J.E., Morgan B.R., Boopathy S., O&#x2019;connor L.C., Bilsel O., Massi F., J&#xe9;gou A., Bosco D.A. ALS-linked PFN1 variants exhibit loss and gain of functions in the context of formin-induced actin polymerization. Proc. Natl. Acad. Sci. USA. 2021;118:e2024605118. doi: 10.1073/pnas.2024605118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2024605118</ArticleId><ArticleId IdType="pmc">PMC8201830</ArticleId><ArticleId IdType="pubmed">34074767</ArticleId></ArticleIdList></Reference><Reference><Citation>Teyssou E., Chartier L., Roussel D., Perera N.D., Nemazanyy I., Langui D., Albert M., Larmonier T., Saker S., Salachas F., et al. The Amyotrophic Lateral Sclerosis M114T PFN1 Mutation Deregulates Alternative Autophagy Pathways and Mitochondrial Homeostasis. Int. J. Mol. Sci. 2022;23:5694. doi: 10.3390/ijms23105694.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23105694</ArticleId><ArticleId IdType="pmc">PMC9143529</ArticleId><ArticleId IdType="pubmed">35628504</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano R., Del Fiore V.S., Bucci C. Role of the Intermediate Filament Protein Peripherin in Health and Disease. Int. J. Mol. Sci. 2022;23:15416. doi: 10.3390/ijms232315416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232315416</ArticleId><ArticleId IdType="pmc">PMC9740141</ArticleId><ArticleId IdType="pubmed">36499746</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellanos-Montiel M.J., Chaineau M., Durcan T.M. The Neglected Genes of ALS: Cytoskeletal Dynamics Impact Synaptic Degeneration in ALS. Front. Cell. Neurosci. 2020;14:594975. doi: 10.3389/fncel.2020.594975.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.594975</ArticleId><ArticleId IdType="pmc">PMC7691654</ArticleId><ArticleId IdType="pubmed">33281562</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrado L., Carlomagno Y., Falasco L., Mellone S., Godi M., Cova E., Cereda C., Testa L., Mazzini L., D&#x2019;Alfonso S. A novel peripherin gene (PRPH) mutation identified in one sporadic amyotrophic lateral sclerosis patient. Neurobiol. Aging. 2011;32:552.e1&#x2013;552.e6. doi: 10.1016/j.neurobiolaging.2010.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.02.011</ArticleId><ArticleId IdType="pubmed">20363051</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson J., Doroudchi M.M., Nguyen M.D., Durham H.D., Strong M.J., Shaw G., Julien J.-P., Mushynski W.E. A neurotoxic peripherin splice variant in a mouse model of ALS. J. Cell Biol. 2003;160:939&#x2013;949. doi: 10.1083/jcb.200205027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200205027</ArticleId><ArticleId IdType="pmc">PMC2173778</ArticleId><ArticleId IdType="pubmed">12642616</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Melo D., Hawley Z.C.E., Strong M.J. Dysregulation of human NEFM and NEFH mRNA stability by ALS-linked miRNAs. Mol. Brain. 2018;11:43. doi: 10.1186/s13041-018-0386-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-018-0386-3</ArticleId><ArticleId IdType="pmc">PMC6054723</ArticleId><ArticleId IdType="pubmed">30029677</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol M.O., Wong T.H., Melhem S., Basu S., Viscusi R., Galjart N., Rozemuller A.J., Fallini C., Landers J.E., Kaat L.D., et al. Novel TUBA4A Variant Associated with Familial Frontotemporal Dementia. Neurol. Genet. 2021;7:e596. doi: 10.1212/NXG.0000000000000596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000596</ArticleId><ArticleId IdType="pmc">PMC8221227</ArticleId><ArticleId IdType="pubmed">34169147</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith B.N., Ticozzi N., Fallini C., Gkazi A.S., Topp S., Kenna K.P., Scotter E.L., Kost J., Keagle P., Miller J.W., et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron. 2014;84:324&#x2013;331. doi: 10.1016/j.neuron.2014.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.09.027</ArticleId><ArticleId IdType="pmc">PMC4521390</ArticleId><ArticleId IdType="pubmed">25374358</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., van Blitterswijk M. Excess of rare damaging TUBA4A variants suggests cytoskeletal defects in ALS. Neuron. 2014;84:241&#x2013;243. doi: 10.1016/j.neuron.2014.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.10.002</ArticleId><ArticleId IdType="pubmed">25374348</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneshmandpour Y., Bahmanpour Z., Kazeminasab S., Moghadam E.A., Alehabib E., Chapi M., Tafakhori A., Aghaei N., Darvish H., Emamalizadeh B. A novel mutation in the ALS2 gene in an iranian kurdish family with juvenile amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2022;24:148&#x2013;151. doi: 10.1080/21678421.2022.2100263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2022.2100263</ArticleId><ArticleId IdType="pubmed">35852402</ArticleId></ArticleIdList></Reference><Reference><Citation>Hand C.K., Devon R.S., Gros-Louis F., Rochefort D., Khoris J., Meininger V., Bouchard J.-P., Camu W., Hayden M.R., Rouleau G.A. Mutation Screening of the ALS2 Gene in Sporadic and Familial Amyotrophic Lateral Sclerosis. Arch. Neurol. 2003;60:1768&#x2013;1771. doi: 10.1001/archneur.60.12.1768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.60.12.1768</ArticleId><ArticleId IdType="pubmed">14676054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Kim S., Nahm M., Li T.-N., Lin H.-C., Kim Y.D., Lee J., Yao C.-K., Lee S. ALS2 regulates endosomal trafficking, postsynaptic development, and neuronal survival. J. Cell Biol. 2021;220:e202007112. doi: 10.1083/jcb.202007112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.202007112</ArticleId><ArticleId IdType="pmc">PMC7944400</ArticleId><ArticleId IdType="pubmed">33683284</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.-Z., Hashemi S.H., Anderson S.K., Huang Y., Moreira M.-C., Lynch D.R., Glass I.A., Chance P.F., Bennett C.L. Senataxin, the yeast Sen1p orthologue: Characterization of a unique protein in which recessive mutations cause ataxia and dominant mutations cause motor neuron disease. Neurobiol. Dis. 2006;23:97&#x2013;108. doi: 10.1016/j.nbd.2006.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.02.007</ArticleId><ArticleId IdType="pubmed">16644229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L., Shi Y., Chen Z., Li S., Zhang J. A novel SETX gene mutation associated with Juvenile amyotrophic lateral sclerosis. Brain Behav. 2018;8:e01066. doi: 10.1002/brb3.1066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.1066</ArticleId><ArticleId IdType="pmc">PMC6160657</ArticleId><ArticleId IdType="pubmed">30052327</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapeli K., Pratt G.A., Vu A.Q., Hutt K.R., Martinez F.J., Sundararaman B., Batra R., Freese P., Lambert N.J., Huelga S.C., et al. Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analyses. Nat. Commun. 2016;7:12143. doi: 10.1038/ncomms12143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12143</ArticleId><ArticleId IdType="pmc">PMC4935974</ArticleId><ArticleId IdType="pubmed">27378374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ticozzi N., Vance C., LeClerc A., Keagle P., Glass J., McKenna-Yasek D., Sapp P., Silani V., Bosco D., Shaw C., et al. Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. Am. J. Med Genet. Part B Neuropsychiatr. Genet. 2011;156:285&#x2013;290. doi: 10.1002/ajmg.b.31158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.b.31158</ArticleId><ArticleId IdType="pubmed">21438137</ArticleId></ArticleIdList></Reference><Reference><Citation>Aluri K.C., Salisbury J.P., Prehn J.H.M., Agar J.N. Loss of angiogenin function is related to earlier ALS onset and a paradoxical increase in ALS duration. Sci. Rep. 2020;10:3715. doi: 10.1038/s41598-020-60431-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-60431-6</ArticleId><ArticleId IdType="pmc">PMC7048737</ArticleId><ArticleId IdType="pubmed">32111867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw W.J., Rehman S., Pham T.T.K., Thiyagarajan N., Lee R.L., Subramanian V., Acharya K.R. Structural insights into human angiogenin variants implicated in Parkinson&#x2019;s disease and Amyotrophic Lateral Sclerosis. Sci. Rep. 2017;7:41996. doi: 10.1038/srep41996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep41996</ArticleId><ArticleId IdType="pmc">PMC5296752</ArticleId><ArticleId IdType="pubmed">28176817</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero W., Shatunov A., Stahl D., Shoai M., van Rheenen W., Jones A.R., Al-Sarraj S., Andersen P.M., Bonini N.M., Conforti F.L., et al. ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiol. Aging. 2017;51:178.e1&#x2013;178.e9. doi: 10.1016/j.neurobiolaging.2016.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.11.010</ArticleId><ArticleId IdType="pmc">PMC5302215</ArticleId><ArticleId IdType="pubmed">28017481</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden A.C., Kim H.J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., Armakola M., Geser F., Greene R., Lu M.M., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Beijer D., Kim H.J., Guo L., O&#x2019;donovan K., Mademan I., Deconinck T., Van Schil K., Fare C.M., Drake L.E., Ford A.F., et al. Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation. J. Clin. Investig. 2021;6:e148363. doi: 10.1172/jci.insight.148363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.148363</ArticleId><ArticleId IdType="pmc">PMC8410042</ArticleId><ArticleId IdType="pubmed">34291734</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda H., Hamasaki H., Wakamiya T., Koyama S., Suzuki S.O., Fujii N., Iwaki T. Loss of hnRNPA1 in ALS spinal cord motor neurons with TDP-43-positive inclusions. Neuropathology. 2014;35:37&#x2013;43. doi: 10.1111/neup.12153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12153</ArticleId><ArticleId IdType="pubmed">25338872</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshaies J.-E., Shkreta L., Moszczynski A.J., Sidib&#xe9; H., Semmler S., Fouillen A., Bennett E.R., Bekenstein U., Destroismaisons L., Toutant J., et al. TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis. Brain. 2018;141:1320&#x2013;1333. doi: 10.1093/brain/awy062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy062</ArticleId><ArticleId IdType="pmc">PMC5917749</ArticleId><ArticleId IdType="pubmed">29562314</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P., Isaacs A.M. The snowball effect of RNA binding protein dysfunction in amyotrophic lateral sclerosis. Brain. 2018;141:1236&#x2013;1238. doi: 10.1093/brain/awy091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy091</ArticleId><ArticleId IdType="pmc">PMC5917769</ArticleId><ArticleId IdType="pubmed">29701791</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik A.M., Barmada S.J. Matrin 3 in neuromuscular disease: Physiology and pathophysiology. J. Clin. Investig. 2021;6:e143948. doi: 10.1172/jci.insight.143948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.143948</ArticleId><ArticleId IdType="pmc">PMC7821588</ArticleId><ArticleId IdType="pubmed">33427209</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.O., Pioro E.P., Boehringer A., Chia R., Feit H., Renton A.E., Pliner H.A., Abramzon Y., Marangi G., Winborn B.J., et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat. Neurosci. 2014;17:664&#x2013;666. doi: 10.1038/nn.3688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3688</ArticleId><ArticleId IdType="pmc">PMC4000579</ArticleId><ArticleId IdType="pubmed">24686783</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehringer A., Garcia-Mansfield K., Singh G., Bakkar N., Pirrotte P., Bowser R. ALS Associated Mutations in Matrin 3 Alter Protein-Protein Interactions and Impede mRNA Nuclear Export. Sci. Rep. 2017;7:14529. doi: 10.1038/s41598-017-14924-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-14924-6</ArticleId><ArticleId IdType="pmc">PMC5674072</ArticleId><ArticleId IdType="pubmed">29109432</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankovic M., Novakovic I., Dawod P.G.A., Dawod A.G.A., Drinic A., Motaleb F.I.A., Ducic S., Nikolic D. Current Concepts on Genetic Aspects of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2021;22:9832. doi: 10.3390/ijms22189832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22189832</ArticleId><ArticleId IdType="pmc">PMC8469731</ArticleId><ArticleId IdType="pubmed">34575995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannwarth S., Ait-El-Mkadem S., Chaussenot A., Genin E.C., Lacas-Gervais S., Fragaki K., Berg-Alonso L., Kageyama Y., Serre V., Moore D.G., et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain. 2014;137:2329&#x2013;2345. doi: 10.1093/brain/awu138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu138</ArticleId><ArticleId IdType="pmc">PMC4107737</ArticleId><ArticleId IdType="pubmed">24934289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Y., Hu J., Che Y., Liu Y., Luo Z., Cheng J., Han Q., He H., Zhou Q. CHCHD2 and CHCHD10 regulate mitochondrial dynamics and integrated stress response. Cell Death Dis. 2022;13:156. doi: 10.1038/s41419-022-04602-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-04602-5</ArticleId><ArticleId IdType="pmc">PMC8850591</ArticleId><ArticleId IdType="pubmed">35173147</ArticleId></ArticleIdList></Reference><Reference><Citation>Straub I.R., Weraarpachai W., A Shoubridge E. Multi-OMICS study of a CHCHD10 variant causing ALS demonstrates metabolic rewiring and activation of endoplasmic reticulum and mitochondrial unfolded protein responses. Hum. Mol. Genet. 2021;30:687&#x2013;705. doi: 10.1093/hmg/ddab078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddab078</ArticleId><ArticleId IdType="pmc">PMC8127406</ArticleId><ArticleId IdType="pubmed">33749723</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E.C., Hounoum B.M., Bannwarth S., Fragaki K., Lacas-Gervais S., Mauri-Crouzet A., Lespinasse F., Neveu J., Ropert B., Aug&#xe9; G., et al. Mitochondrial defect in muscle precedes neuromuscular junction degeneration and motor neuron death in CHCHD10S59L/+ mouse. Acta Neuropathol. 2019;138:123&#x2013;145. doi: 10.1007/s00401-019-01988-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01988-z</ArticleId><ArticleId IdType="pubmed">30874923</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E.C., Bannwarth S., Lespinasse F., Ortega-Vila B., Fragaki K., Itoh K., Villa E., Lacas-Gervais S., Jokela M., Auranen M., et al. Loss of MICOS complex integrity and mitochondrial damage, but not TDP-43 mitochondrial localisation, are likely associated with severity of CHCHD10-related diseases. Neurobiol. Dis. 2018;119:159&#x2013;171. doi: 10.1016/j.nbd.2018.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.07.027</ArticleId><ArticleId IdType="pmc">PMC7015038</ArticleId><ArticleId IdType="pubmed">30092269</ArticleId></ArticleIdList></Reference><Reference><Citation>Straub I.R., Janer A., Weraarpachai W., Zinman L., Robertson J., Rogaeva E., Shoubridge E.A. Loss of CHCHD10-CHCHD2 complexes required for respiration underlies the pathogenicity of a CHCHD10 mutation in ALS. Hum. Mol. Genet. 2018;27:178&#x2013;189. doi: 10.1093/hmg/ddx393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx393</ArticleId><ArticleId IdType="pmc">PMC5886208</ArticleId><ArticleId IdType="pubmed">29121267</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockmann S.J., Freischmidt A., Oeckl P., M&#xfc;ller K., Ponna S.K., Helferich A.M., Paone C., Reinders J., Kojer K., Orth M., et al. CHCHD10 mutations p.R15L and p.G66V cause motoneuron disease by haploinsufficiency. Hum. Mol. Genet. 2018;27:706&#x2013;715. doi: 10.1093/hmg/ddx436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx436</ArticleId><ArticleId IdType="pubmed">29315381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T., Su T.-P. Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival. Cell. 2007;131:596&#x2013;610. doi: 10.1016/j.cell.2007.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.08.036</ArticleId><ArticleId IdType="pubmed">17981125</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukunaga K., Shinoda Y., Tagashira H. The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis. J. Pharmacol. Sci. 2015;127:36&#x2013;41. doi: 10.1016/j.jphs.2014.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphs.2014.12.012</ArticleId><ArticleId IdType="pubmed">25704016</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreser A., Vollrath J.T., Sechi A., Johann S., Roos A., Yamoah A., Katona I., Bohlega S., Wiemuth D., Tian Y., et al. The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins. Cell Death Differ. 2017;24:1655&#x2013;1671. doi: 10.1038/cdd.2017.88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2017.88</ArticleId><ArticleId IdType="pmc">PMC5596426</ArticleId><ArticleId IdType="pubmed">28622300</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y., Fukuda Y., Yoshimura J., Toyoda A., Kurppa K., Moritoyo H., Belzil V.V., Dion P.A., Higasa K., Doi K., et al. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am. J. Hum. Genet. 2013;93:900&#x2013;905. doi: 10.1016/j.ajhg.2013.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.09.008</ArticleId><ArticleId IdType="pmc">PMC3824132</ArticleId><ArticleId IdType="pubmed">24119685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Liu X., He J., Zhang N., Chen L., Tang L., Fan D. Analysis of ERBB4 Variants in Amyotrophic Lateral Sclerosis Within a Chinese Cohort. Front. Neurol. 2022;13:865264. doi: 10.3389/fneur.2022.865264.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.865264</ArticleId><ArticleId IdType="pmc">PMC9035935</ArticleId><ArticleId IdType="pubmed">35481267</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahm M., Lim S.M., Kim Y.-E., Park J., Noh M.-Y., Lee S., Roh J.E., Hwang S.-M., Park C.-K., Kim Y.H., et al. ANXA11 mutations in ALS cause dysregulation of calcium homeostasis and stress granule dynamics. Sci. Transl. Med. 2020;12:eaax3993. doi: 10.1126/scitranslmed.aax3993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aax3993</ArticleId><ArticleId IdType="pubmed">33087501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Duan X., Zhou X., Wang R., Zhang X., Cao Z., Wang X., Zhou Z., Sun Y., Peng D. ANXA11 mutations are associated with amyotrophic lateral sclerosis-frontotemporal dementia. Front. Neurol. 2022;13:886887. doi: 10.3389/fneur.2022.886887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.886887</ArticleId><ArticleId IdType="pmc">PMC9549789</ArticleId><ArticleId IdType="pubmed">36226077</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung W., Nahm M., Lim S.M., Noh M.-Y., Lee S., Hwang S.-M., Kim Y.H., Park J., Oh K.-W., Ki C.-S., et al. Clinical and genetic characteristics of amyotrophic lateral sclerosis patients with ANXA11 variants. Brain Commun. 2022;4:fcac299. doi: 10.1093/braincomms/fcac299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac299</ArticleId><ArticleId IdType="pmc">PMC9707645</ArticleId><ArticleId IdType="pubmed">36458208</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C., Yang K., Wu X., Zhang Y., Shan S., Gitler A., Ghosh A., Qiu Z. Loss of CREST leads to neuroinflammatory responses and ALS-like motor defects in mice. Transl. Neurodegener. 2019;8:13. doi: 10.1186/s40035-019-0152-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-019-0152-1</ArticleId><ArticleId IdType="pmc">PMC6444434</ArticleId><ArticleId IdType="pubmed">30976389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondori N.R., Paul P., Robbins J.P., Liu K., Hildyard J.C.W., Wells D.J., De Belleroche J.S. Focus on the Role of D-serine and D-amino Acid Oxidase in Amyotrophic Lateral Sclerosis/Motor Neuron Disease (ALS) Front. Mol. Biosci. 2018;5:8. doi: 10.3389/fmolb.2018.00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2018.00008</ArticleId><ArticleId IdType="pmc">PMC5816792</ArticleId><ArticleId IdType="pubmed">29487852</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell J., Paul P., Chen H.-J., Morris A., Payling M., Falchi M., Habgood J., Panoutsou S., Winkler S., Tisato V., et al. Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc. Natl. Acad. Sci. USA. 2010;107:7556&#x2013;7561. doi: 10.1073/pnas.0914128107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0914128107</ArticleId><ArticleId IdType="pmc">PMC2867752</ArticleId><ArticleId IdType="pubmed">20368421</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin S., Blauw H.M., Veldink J.H., van Es M.A., Ophoff R.A., Bradley D.G., Berg L.H.v.D., Hardiman O. Analysis of genome-wide copy number variation in Irish and Dutch ALS populations. Hum. Mol. Genet. 2008;17:3392&#x2013;3398. doi: 10.1093/hmg/ddn233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn233</ArticleId><ArticleId IdType="pubmed">18689356</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X.-B., Cui N.-H., Gao J.-J., Qiu X.-P., Zheng F. SMN1 duplications contribute to sporadic amyotrophic lateral sclerosis susceptibility: Evidence from a meta-analysis. J. Neurol. Sci. 2014;340:63&#x2013;68. doi: 10.1016/j.jns.2014.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.02.026</ArticleId><ArticleId IdType="pubmed">24630593</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P., Camu W., Halimi J.M., Vourc&#x2019;h P., Antar C., Vedrine S., Giraudeau B., de Toffol B., Andres C.R., French ALS Study Group SMN1 gene, but not SMN2, is a risk factor for sporadic ALS. Neurology. 2006;67:1147&#x2013;1150. doi: 10.1212/01.wnl.0000233830.85206.1e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000233830.85206.1e</ArticleId><ArticleId IdType="pubmed">16931506</ArticleId></ArticleIdList></Reference><Reference><Citation>Moisse M., Zwamborn R.A.J., Vugt J., Spek R., Rheenen W., Kenna B., Van Eijk K., Kenna K., Corcia P., Couratier P., et al. The Effect of SMN Gene Dosage on ALS Risk and Disease Severity. Ann. Neurol. 2021;89:686&#x2013;697. doi: 10.1002/ana.26009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26009</ArticleId><ArticleId IdType="pmc">PMC8048961</ArticleId><ArticleId IdType="pubmed">33389754</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauw H.M., Veldink J.H., van Es M.A., van Vught P.W., Saris C.G., van der Zwaag B., Franke L., Burbach J.P., Wokke J.H., Ophoff R.A., et al. Copy-number variation in sporadic amyotrophic lateral sclerosis: A genome-wide screen. Lancet Neurol. 2008;7:319&#x2013;326. doi: 10.1016/S1474-4422(08)70048-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70048-6</ArticleId><ArticleId IdType="pubmed">18313986</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauw H.M., Al-Chalabi A., Andersen P.M., van Vught P.W., Diekstra F.P., van Es M.A., Saris C.G., Groen E.J., van Rheenen W., Koppers M., et al. A large genome scan for rare CNVs in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2010;19:4091&#x2013;4099. doi: 10.1093/hmg/ddq323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq323</ArticleId><ArticleId IdType="pubmed">20685689</ArticleId></ArticleIdList></Reference><Reference><Citation>Robelin L., De Aguilar J.L.G. Blood Biomarkers for Amyotrophic Lateral Sclerosis: Myth or Reality? BioMed Res. Int. 2014;2014:525097. doi: 10.1155/2014/525097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/525097</ArticleId><ArticleId IdType="pmc">PMC4060749</ArticleId><ArticleId IdType="pubmed">24991560</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarasiuk J., Ku&#x142;akowska A., Drozdowski W., Kornhuber J., Lewczuk P. CSF markers in amyotrophic lateral sclerosis. J. Neural Transm. 2012;119:747&#x2013;757. doi: 10.1007/s00702-012-0806-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-012-0806-y</ArticleId><ArticleId IdType="pubmed">22555610</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghunathan R., Turajane K., Wong L.C. Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson&#x2019;s Disease. Int. J. Mol. Sci. 2022;23:9299. doi: 10.3390/ijms23169299.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23169299</ArticleId><ArticleId IdType="pmc">PMC9409485</ArticleId><ArticleId IdType="pubmed">36012563</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter L., Shoushtarizadeh A., Jelinek G.A., Brown C.R., Lim C.K., De Livera A.M., Jacobs K.R., Weiland T.J. Metabolomic Biomarkers of Multiple Sclerosis: A Systematic Review. Front. Mol. Biosci. 2020;7:574133. doi: 10.3389/fmolb.2020.574133.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.574133</ArticleId><ArticleId IdType="pmc">PMC7768024</ArticleId><ArticleId IdType="pubmed">33381517</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A.C., Pradat P.-F., Mendon&#xe7;a D.M.F., Manzano R. Decoding amyotrophic lateral sclerosis: Discovery of novel disease-related biomarkers and future perspectives in neurodegeneration. BioMed Res. Int. 2014;2014:629630. doi: 10.1155/2014/629630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/629630</ArticleId><ArticleId IdType="pmc">PMC4137629</ArticleId><ArticleId IdType="pubmed">25162018</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat P.-F., Dubourg O., de Tapia M., di Scala F., Dupuis L., Lenglet T., Bruneteau G., Salachas F., Lacomblez L., Corvol J.-C., et al. Muscle gene expression is a marker of amyotrophic lateral sclerosis severity. Neurodegener. Dis. 2011;9:38&#x2013;52. doi: 10.1159/000329723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000329723</ArticleId><ArticleId IdType="pubmed">21934272</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q., Zhao X., Li S., Yang F., Wang H., Cui F., Huang X. CSF Neurofilament Light Chain Elevation Predicts ALS Severity and Progression. Front. Neurol. 2020;11:919. doi: 10.3389/fneur.2020.00919.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00919</ArticleId><ArticleId IdType="pmc">PMC7484044</ArticleId><ArticleId IdType="pubmed">32982935</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R., Copetti M., Ruggieri M., Cortese R., Capozzo R., Leo A., D&#x2019;Errico E., Mastrapasqua M., Zoccolella S., Pellegrini F., et al. Cerebrospinal fluid neurofilament light chain levels: Marker of progression to generalized amyotrophic lateral sclerosis. Eur. J. Neurol. 2015;22:215&#x2013;218. doi: 10.1111/ene.12421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12421</ArticleId><ArticleId IdType="pubmed">24750431</ArticleId></ArticleIdList></Reference><Reference><Citation>King A.E., Blizzard C.A., Southam K.A., Vickers J.C., Dickson T.C. Degeneration of axons in spinal white matter in G93A mSOD1 mouse characterized by NFL and &#x3b1;-internexin immunoreactivity. Brain Res. 2012;1465:90&#x2013;100. doi: 10.1016/j.brainres.2012.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.05.018</ArticleId><ArticleId IdType="pubmed">22609817</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgrave L.M., Ma M., Best J.R., DeMarco M.L. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer&#x2019;s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Alzheimer&#x2019;s Dement. 2019;11:730&#x2013;743. doi: 10.1016/j.dadm.2019.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2019.08.009</ArticleId><ArticleId IdType="pmc">PMC6939029</ArticleId><ArticleId IdType="pubmed">31909174</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F., Steinacker P., Weishaupt J.H., Kassubek J., Oeckl P., Halbgebauer S., Tumani H., von Arnim C.A.F., Dorst J., Feneberg E., et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:157&#x2013;164. doi: 10.1136/jnnp-2018-318704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacchiano V., Mastrangelo A., Zenesini C., Masullo M., Quadalti C., Avoni P., Polischi B., Cherici A., Capellari S., Salvi F., et al. Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study. Front. Aging Neurosci. 2021;13:753242. doi: 10.3389/fnagi.2021.753242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.753242</ArticleId><ArticleId IdType="pmc">PMC8569186</ArticleId><ArticleId IdType="pubmed">34744694</ArticleId></ArticleIdList></Reference><Reference><Citation>Behzadi A., Pujol-Calder&#xf3;n F., Tjust A.E., Wuolikainen A., H&#xf6;glund K., Forsberg K., Portelius E., Blennow K., Zetterberg H., Andersen P.M. Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. Sci. Rep. 2021;11:22128. doi: 10.1038/s41598-021-01499-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-01499-6</ArticleId><ArticleId IdType="pmc">PMC8585882</ArticleId><ArticleId IdType="pubmed">34764380</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M., Jeromin A., Gille B., Claeys K., Herbst V., Brix B., Van Damme P., Poesen K. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2018;89:367&#x2013;373. doi: 10.1136/jnnp-2017-316605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316605</ArticleId><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.-H., Petzold A., Topping J., Allen K., Macdonald-Wallis C., Clarke J., Pearce N., Kuhle J., Giovannoni G., Fratta P., et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: Insights from a longitudinal study. J. Neurol. Neurosurg. Psychiatry. 2015;86:565&#x2013;573. doi: 10.1136/jnnp-2014-307672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-307672</ArticleId><ArticleId IdType="pmc">PMC4413806</ArticleId><ArticleId IdType="pubmed">25009280</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marchi F., Munitic I., Amedei A., Berry J.D., Feldman E.L., Aronica E., Nardo G., Van Weehaeghe D., Niccolai E., Prtenjaca N., et al. Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. Neurosci. Biobehav. Rev. 2021;127:958&#x2013;978. doi: 10.1016/j.neubiorev.2021.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2021.06.027</ArticleId><ArticleId IdType="pmc">PMC8428677</ArticleId><ArticleId IdType="pubmed">34153344</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Cao C., Qin X.-Y., Yu Y., Yuan J., Zhao Y., Cheng Y. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: A meta-analysis study. Sci. Rep. 2017;7:9094. doi: 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.-H., Allen K., Oei F., Leoni E., Kuhle J., Tree T., Fratta P., Sharma N., Sidle K., Howard R., et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2016;3:e244. doi: 10.1212/NXI.0000000000000244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000244</ArticleId><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelson N., Facciponte D., Bradley W., Stommel E. Cytokine expression levels in ALS: A potential link between inflammation and BMAA-triggered protein misfolding. Cytokine Growth Factor Rev. 2017;37:81&#x2013;88. doi: 10.1016/j.cytogfr.2017.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2017.05.001</ArticleId><ArticleId IdType="pubmed">28532674</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R., Zecca C., Piccininni M., Benmahamed S., Dell&#x2019;Abate M.T., Barulli M.R., Capozzo R., Battista P., Logroscino G. Plasma Inflammatory Cytokines Are Elevated in ALS. Front. Neurol. 2020;11:552295. doi: 10.3389/fneur.2020.552295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.552295</ArticleId><ArticleId IdType="pmc">PMC7691268</ArticleId><ArticleId IdType="pubmed">33281700</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Garcon G., Patin F., Veyrat-Durebex C., Boyer J., Devos D., Vourc&#x2019;h P., Andres C.R., Corcia P. Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study. Can. J. Neurol. Sci./J. Can. des Sci. Neurol. 2017;44:90&#x2013;95. doi: 10.1017/cjn.2016.284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cjn.2016.284</ArticleId><ArticleId IdType="pubmed">27774920</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao M.C., Cawston E.E., Chen G., Brooks C., Douwes J., McLean D., Graham E.S., Dragunow M., Scotter E.L. Serum biomarkers of neuroinflammation and blood-brain barrier leakage in amyotrophic lateral sclerosis. BMC Neurol. 2022;22:216. doi: 10.1186/s12883-022-02730-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-022-02730-1</ArticleId><ArticleId IdType="pmc">PMC9188104</ArticleId><ArticleId IdType="pubmed">35690735</ArticleId></ArticleIdList></Reference><Reference><Citation>Paladino P., Valentino F., Piccoli T., Piccoli F., La Bella V. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Eur. J. Neurol. 2009;16:257&#x2013;261. doi: 10.1111/j.1468-1331.2008.02405.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2008.02405.x</ArticleId><ArticleId IdType="pubmed">19138331</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarafino A., D&#x2019;errico E., Introna A., Fraddosio A., Distaso E., Tempesta I., Morea A., Mastronardi A., Leante R., Ruggieri M., et al. Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis. J. Neurol. 2018;265:2353&#x2013;2362. doi: 10.1007/s00415-018-9008-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-9008-3</ArticleId><ArticleId IdType="pubmed">30116940</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima Y., Kasai T., Noto Y.-I., Ohmichi T., Tatebe H., Kitaoji T., Tsuji Y., Kitani-Morii F., Shinomoto M., Allsop D., et al. Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics. PLoS ONE. 2021;16:e0260323. doi: 10.1371/journal.pone.0260323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260323</ArticleId><ArticleId IdType="pmc">PMC8629269</ArticleId><ArticleId IdType="pubmed">34843548</ArticleId></ArticleIdList></Reference><Reference><Citation>Thapa S., Bhattarai A., Shah S., Chand S., Bagherieh S., Mirmosayyeb O., Mishra S.K. Diagnostic Role of Tau Proteins in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. Acta Neurologica. Scandinavica. 2023;2023:2791622. doi: 10.1155/2023/2791622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2023/2791622</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Carrero J.J., Zagai U., Evans M., Ingre C., Pawitan Y., Fang F. Blood biomarkers and prognosis of amyotrophic lateral sclerosis. Eur. J. Neurol. 2020;27:2125&#x2013;2133. doi: 10.1111/ene.14409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14409</ArticleId><ArticleId IdType="pubmed">32557963</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T.F., Daughrity L.M., Heckman M.G., Diehl N.N., Wuu J., Miller T.M., Pastor P., Trojanowski J.Q., Grossman M., Berry J.D., et al. Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF 72 -associated amyotrophic lateral sclerosis. Ann. Neurol. 2017;82:139&#x2013;146. doi: 10.1002/ana.24980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24980</ArticleId><ArticleId IdType="pmc">PMC5676468</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A., Martinelli I., Bello L., Querin G., Puthenparampil M., Ruggero S., Toffanin E., Cagnin A., Briani C., Pegoraro E., et al. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease. JAMA Neurol. 2017;74:525&#x2013;532. doi: 10.1001/jamaneurol.2016.5398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.5398</ArticleId><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamerlan A.M., Shim K.H., Youn Y.C., Teunissen C., An S.S.A., Scheltens P., Kim S. Increased oligomeric TDP-43 in the plasma of Korean frontotemporal dementia patients with semantic dementia. Alzheimer&#x2019;s Dement. 2023 doi: 10.1002/alz.13127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.13127</ArticleId><ArticleId IdType="pubmed">37200243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T., Tokuda T., Ishigami N., Sasayama H., Foulds P., Mitchell D.J., Mann D.M.A., Allsop D., Nakagawa M. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009;117:55&#x2013;62. doi: 10.1007/s00401-008-0456-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0456-1</ArticleId><ArticleId IdType="pubmed">18989684</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer L., G&#xfc;nther R., Koch J.C., Klebe S., Hagenacker T., Lingor P., Biesalski A.S., Hermann A., Nabers A., Gold R., et al. TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2021;8:271&#x2013;277. doi: 10.1002/acn3.51256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51256</ArticleId><ArticleId IdType="pmc">PMC7818221</ArticleId><ArticleId IdType="pubmed">33263951</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B., De Schaepdryver M., Dedeene L., Goossens J., Claeys K.G., Van Den Bosch L., Tournoy J., Van Damme P., Poesen K. Inflammatory markers in cerebrospinal fluid: Independent prognostic biomarkers in amyotrophic lateral sclerosis? J. Neurol. Neurosurg. Psychiatry. 2019;90:1338&#x2013;1346. doi: 10.1136/jnnp-2018-319586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Demestre M., Parkin-Smith G., Petzold A., Pullen A. The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J. Neuroimmunol. 2005;159:146&#x2013;154. doi: 10.1016/j.jneuroim.2004.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2004.09.015</ArticleId><ArticleId IdType="pubmed">15652414</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x141;ukaszewicz-Zaj&#x105;c M., Mroczko B., S&#x142;owik A. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS) J. Neural Transm. 2014;121:1387&#x2013;1397. doi: 10.1007/s00702-014-1205-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-014-1205-3</ArticleId><ArticleId IdType="pmc">PMC4210652</ArticleId><ArticleId IdType="pubmed">25047909</ArticleId></ArticleIdList></Reference><Reference><Citation>Soko&#x142;owska B., J&#xf3;&#x17a;wik A., Niebroj-Dobosz I., Janik P., Kwiecinski H. Evaluation of matrix metalloproteinases in serum of patients with amyotrophic lateral sclerosis with pattern recognition methods. J. Physiol. Pharmacol. 2009;60((Suppl. S5)):117&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">20134051</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin K.E., Jasin P., Braunstein K.E., Sinha I., Bowden K.D., Moghekar A., Oh E.S., Raitcheva D., Bartlett D., Berry J.D., et al. A fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALS. bioRxiv. 20232023.01.23.525202</Citation></Reference><Reference><Citation>Gendron T.F., Chew J., Stankowski J.N., Hayes L.R., Zhang Y.-J., Prudencio M., Carlomagno Y., Daughrity L.M., Jansen-West K., Perkerson E.A., et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:eaai7866. doi: 10.1126/scitranslmed.aai7866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7866</ArticleId><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan G., Raitcheva D., Bartlett D., Prudencio M., McKenna-Yasek D.M., Douthwright C., Oskarsson B.E., Ladha S., King O.D., Barmada S.J., et al. Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD. Nat. Commun. 2022;13:2799. doi: 10.1038/s41467-022-30387-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30387-4</ArticleId><ArticleId IdType="pmc">PMC9119980</ArticleId><ArticleId IdType="pubmed">35589711</ArticleId></ArticleIdList></Reference><Reference><Citation>Gertsman I., Wuu J., McAlonis-Downes M., Ghassemian M., Ling K., Rigo F., Bennett F., Benatar M., Miller T.M., Da Cruz S. An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis. JCI Investig. 2019;4:e122768. doi: 10.1172/jci.insight.122768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.122768</ArticleId><ArticleId IdType="pmc">PMC6542602</ArticleId><ArticleId IdType="pubmed">31092730</ArticleId></ArticleIdList></Reference><Reference><Citation>Winer L., Srinivasan D., Chun S., Lacomis D., Jaffa M., Fagan A., Holtzman D.M., Wancewicz E., Bennett C.F., Bowser R., et al. SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy. JAMA Neurol. 2013;70:201&#x2013;207. doi: 10.1001/jamaneurol.2013.593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.593</ArticleId><ArticleId IdType="pmc">PMC3812918</ArticleId><ArticleId IdType="pubmed">23147550</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Gray E., Bampton A., Raciborska D., Talbot K., Turner M.R. CSF chitinase proteins in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:1215&#x2013;1220. doi: 10.1136/jnnp-2019-320442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320442</ArticleId><ArticleId IdType="pubmed">31123140</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Verde F., Fang L., Feneberg E., Oeckl P., Roeber S., Anderl-Straub S., Danek A., Diehl-Schmid J., Fassbender K., et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J. Neurol. Neurosurg. Psychiatry. 2018;89:239&#x2013;247. doi: 10.1136/jnnp-2017-317138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317138</ArticleId><ArticleId IdType="pubmed">29142138</ArticleId></ArticleIdList></Reference><Reference><Citation>Niebroj-Dobosz I., Janik P., Soko&#x142;owska B., Kwiecinski H. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 2010;17:226&#x2013;231. doi: 10.1111/j.1468-1331.2009.02775.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02775.x</ArticleId><ArticleId IdType="pubmed">19796283</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe5;nberg A., Skene N., Sanders F., Trusohamn M., Remnest&#xe5;l J., Szczepi&#x144;ska A., Aksoylu I.S., L&#xf6;nnerberg P., Ebarasi L., Wouters S., et al. Altered perivascular fibroblast activity precedes ALS disease onset. Nat. Med. 2021;27:640&#x2013;646. doi: 10.1038/s41591-021-01295-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01295-9</ArticleId><ArticleId IdType="pmc">PMC7613336</ArticleId><ArticleId IdType="pubmed">33859435</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaur N., Perner C., Witte O.W., Grosskreutz J. The Chitinases as Biomarkers for Amyotrophic Lateral Sclerosis: Signals From the CNS and Beyond. Front. Neurol. 2020;11:377. doi: 10.3389/fneur.2020.00377.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00377</ArticleId><ArticleId IdType="pmc">PMC7267218</ArticleId><ArticleId IdType="pubmed">32536900</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., Lashley T., Norona F.E., Clayton E.L., Ridler C.E., Fratta P., Isaacs A.M. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 2013;126:845&#x2013;857. doi: 10.1007/s00401-013-1200-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1200-z</ArticleId><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Lombardi V., Malaspina A. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol. 2018;84:130&#x2013;139. doi: 10.1002/ana.25276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benigni M., Ricci C., Jones A.R., Giannini F., Al-Chalabi A., Battistini S. Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients. NeuroMolecular Med. 2016;18:551&#x2013;560. doi: 10.1007/s12017-016-8396-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-016-8396-8</ArticleId><ArticleId IdType="pubmed">27119371</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbo M., Ravnik-Glava&#x10d; M. Extracellular Vesicles as Potential Biomarkers in Amyotrophic Lateral Sclerosis. Genes. 2023;14:325. doi: 10.3390/genes14020325.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes14020325</ArticleId><ArticleId IdType="pmc">PMC9956314</ArticleId><ArticleId IdType="pubmed">36833252</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X., Ma M., Teng J., Teng R.K., Zhou S., Yin J., Fonkem E., Huang J.H., Wu E., Wang X. Exposure to ALS-FTD-CSF generates TDP-43 aggregates in glioblastoma cells through exosomes and TNTs-like structure. Oncotarget. 2015;6:24178&#x2013;24191. doi: 10.18632/oncotarget.4680.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.4680</ArticleId><ArticleId IdType="pmc">PMC4695178</ArticleId><ArticleId IdType="pubmed">26172304</ArticleId></ArticleIdList></Reference><Reference><Citation>An Y.R., Hwang S.Y. Toxicology study with microRNA. Mol. Cell. Toxicol. 2014;10:127&#x2013;134. doi: 10.1007/s13273-014-0014-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13273-014-0014-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H., Pyo J.Y., Moon J., Lee S., Kim M., Choi Y., Shin D.-I., Park B.-G. Identification of miRNA expression associated with Alzheimer&#x2019;s disease and neurodegeneration in rat models with obstructive sleep apnea. Mol. Cell. Toxicol. 2022 doi: 10.1007/s13273-022-00309-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13273-022-00309-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Melo D., Droppelmann C.A., He Z., Volkening K., Strong M.J. Altered microRNA expression profile in amyotrophic lateral sclerosis: A role in the regulation of NFL mRNA levels. Mol. Brain. 2013;6:26. doi: 10.1186/1756-6606-6-26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-6-26</ArticleId><ArticleId IdType="pmc">PMC3668997</ArticleId><ArticleId IdType="pubmed">23705811</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Wei Q., Chen X., Li C., Cao B., Ou R., Hadano S., Shang H.-F. Aberration of miRNAs Expression in Leukocytes from Sporadic Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2016;9:69. doi: 10.3389/fnmol.2016.00069.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2016.00069</ArticleId><ArticleId IdType="pmc">PMC4987348</ArticleId><ArticleId IdType="pubmed">27582688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi N., Doi H., Kurata Y., Kagawa H., Atobe Y., Funakoshi K., Tada M., Katsumoto A., Tanaka K., Kunii M., et al. Proteomic analysis of exosome-enriched fractions derived from cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurosci. Res. 2020;160:43&#x2013;49. doi: 10.1016/j.neures.2019.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2019.10.010</ArticleId><ArticleId IdType="pubmed">31669371</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice B., Annunziata A., Fiorentino G., Borra M., Biffali E., Coppola C., Cotrufo R., Brettschneider J., Giordana M.L., Dalmay T., et al. miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics. 2014;15:243&#x2013;253. doi: 10.1007/s10048-014-0420-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-014-0420-2</ArticleId><ArticleId IdType="pubmed">25130371</ArticleId></ArticleIdList></Reference><Reference><Citation>Magen I., Yacovzada N.S., Yanowski E., Coenen-Stass A., Grosskreutz J., Lu C.-H., Greensmith L., Malaspina A., Fratta P., Hornstein E. Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. Nat. Neurosci. 2021;24:1534&#x2013;1541. doi: 10.1038/s41593-021-00936-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00936-z</ArticleId><ArticleId IdType="pubmed">34711961</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R., Goodall E.F., Milo M., Cooper-Knock J., Da Costa M., Hobson E., Kazoka M., Wollff H., Heath P.R., Shaw P.J., et al. Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS) Neurobiol. Aging. 2017;55:123&#x2013;131. doi: 10.1016/j.neurobiolaging.2017.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.03.027</ArticleId><ArticleId IdType="pmc">PMC5455071</ArticleId><ArticleId IdType="pubmed">28454844</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero D., Gagliardi S., Zucca S., Arigoni M., Giannini M., Garofalo M., Olivero M., Dell&#x2019;orco M., Pansarasa O., Bernuzzi S., et al. Different miRNA Profiles in Plasma Derived Small and Large Extracellular Vesicles from Patients with Neurodegenerative Diseases. Int. J. Mol. Sci. 2021;22:2737. doi: 10.3390/ijms22052737.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052737</ArticleId><ArticleId IdType="pmc">PMC7962970</ArticleId><ArticleId IdType="pubmed">33800495</ArticleId></ArticleIdList></Reference><Reference><Citation>Banack S.A., Dunlop R.A., Stommel E.W., Mehta P., Cox P.A. miRNA extracted from extracellular vesicles is a robust biomarker of amyotrophic lateral sclerosis. J. Neurol. Sci. 2022;442:120396. doi: 10.1016/j.jns.2022.120396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120396</ArticleId><ArticleId IdType="pubmed">36081303</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Wang S.K., Zhang Y., Rostami A., Kenkare A., Casella G., Yuan Z.Q., Li X. Role of extracellular vesicles in neurodegenerative diseases. Prog. Neurobiol. 2021;201:102022.</Citation><ArticleIdList><ArticleId IdType="pubmed">33617919</ArticleId></ArticleIdList></Reference><Reference><Citation>McCluskey G., Morrison K.E., Donaghy C., Rene F., Duddy W., Duguez S. Extracellular Vesicles in Amyotrophic Lateral Sclerosis. Life. 2022;13:121. doi: 10.3390/life13010121.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13010121</ArticleId><ArticleId IdType="pmc">PMC9867379</ArticleId><ArticleId IdType="pubmed">36676070</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero D., Gagliardi S., Zucca S., Arigoni M., Giannini M., Garofalo M., Fantini V., Pansarasa O., Avenali M., Ramusino M.C., et al. Extracellular Vesicles Derived from Plasma of Patients with Neurodegenerative Disease Have Common Transcriptomic Profiling. Front. Aging Neurosci. 2022;14:785741. doi: 10.3389/fnagi.2022.785741.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.785741</ArticleId><ArticleId IdType="pmc">PMC8889100</ArticleId><ArticleId IdType="pubmed">35250537</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano A., Ettcheto M., Bernuz M., Puerta R., Esteban de Antonio E., S&#xe1;nchez-L&#xf3;pez E., Souto E.B., Camins A., Mart&#xed; M., Pividori M.I., et al. Extracellular vesicles, the emerging mirrors of brain physiopathology. Int. J. Biol. Sci. 2023;19:721&#x2013;743. doi: 10.7150/ijbs.79063.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.79063</ArticleId><ArticleId IdType="pmc">PMC9910004</ArticleId><ArticleId IdType="pubmed">36778117</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P.-C., Wu D., Hu C.-J., Chen H.-Y., Hsieh Y.-C., Huang C.-C. Exosomal TAR DNA-binding protein-43 and neurofilaments in plasma of amyotrophic lateral sclerosis patients: A longitudinal follow-up study. J. Neurol. Sci. 2020;418:117070117070. doi: 10.1016/j.jns.2020.117070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117070</ArticleId><ArticleId IdType="pubmed">32836016</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasetto L., Callegaro S., Corbelli A., Fiordaliso F., Ferrara D., Brunelli L., Sestito G., Pastorelli R., Bianchi E., Cretich M., et al. Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis. Mol. Neurodegener. 2021;16:52. doi: 10.1186/s13024-021-00470-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00470-3</ArticleId><ArticleId IdType="pmc">PMC8353748</ArticleId><ArticleId IdType="pubmed">34376243</ArticleId></ArticleIdList></Reference><Reference><Citation>Pregnolato F., Cova L., Doretti A., Bardelli D., Silani V., Bossolasco P. Exosome microRNAs in Amyotrophic Lateral Sclerosis: A Pilot Study. Biomolecules. 2021;11:1220. doi: 10.3390/biom11081220.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11081220</ArticleId><ArticleId IdType="pmc">PMC8394507</ArticleId><ArticleId IdType="pubmed">34439885</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Xia K., Chen L., Fan D. Increased Interleukin-6 Levels in the Astrocyte-Derived Exosomes of Sporadic Amyotrophic Lateral Sclerosis Patients. Front. Neurosci. 2019;13:574. doi: 10.3389/fnins.2019.00574.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00574</ArticleId><ArticleId IdType="pmc">PMC6560167</ArticleId><ArticleId IdType="pubmed">31231184</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhasmana S., Dhasmana A., Narula A.S., Jaggi M., Yallapu M.M., Chauhan S.C. The panoramic view of amyotrophic lateral sclerosis: A fatal intricate neurological disorder. Life Sci. 2022;288:120156. doi: 10.1016/j.lfs.2021.120156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.120156</ArticleId><ArticleId IdType="pubmed">34801512</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor B.J. A roadmap for genetic testing in ALS. J. Neurol. Neurosurg. Psychiatry. 2014;85:476. doi: 10.1136/jnnp-2013-305726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-305726</ArticleId><ArticleId IdType="pmc">PMC4568817</ArticleId><ArticleId IdType="pubmed">23868946</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Battistini S., Calvo A., Caponnetto C., Conforti F.L., Corbo M., Giannini F., Mandrioli J., Mora G., Sabatelli M., et al. Genetic counselling in ALS: Facts, uncertainties and clinical suggestions. J. Neurol. Neurosurg. Psychiatry. 2014;85:478&#x2013;485. doi: 10.1136/jnnp-2013-305546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-305546</ArticleId><ArticleId IdType="pubmed">23833266</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzel S., Mayer K., Oeckl P. Biomarkers for amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2022;35:699&#x2013;704. doi: 10.1097/WCO.0000000000001094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000001094</ArticleId><ArticleId IdType="pubmed">35942674</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinchetti P., Rizzuti M., Faravelli I., Corti S. MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2018;55:2617&#x2013;2630. doi: 10.1007/s12035-017-0537-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0537-z</ArticleId><ArticleId IdType="pubmed">28421535</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Zhou F., Guan Y., Meng F., Zhao Z., Su Q., Bao W., Wang X., Zhao J., Huo Z., et al. The Biogenesis of miRNAs and Their Role in the Development of Amyotrophic Lateral Sclerosis. Cells. 2022;11:572. doi: 10.3390/cells11030572.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11030572</ArticleId><ArticleId IdType="pmc">PMC8833997</ArticleId><ArticleId IdType="pubmed">35159383</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal N.A., Berry J.D., Windebank A., Staff N.P., Maragakis N.J., Berg L.H.V.D., Genge A., Miller R., Baloh R.H., Kern R., et al. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve. 2020;62:156&#x2013;166. doi: 10.1002/mus.26801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26801</ArticleId><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E., Mennini T., Bendotti C., Bigini P., Logroscino G., Chio A., Hardiman O., Mitchell D., Swingler R., Traynor B., et al. The Heterogeneity of Amyotrophic Lateral Sclerosis: A Possible Explanation of Treatment Failure. Curr. Med. Chem. 2007;14:3185&#x2013;3200. doi: 10.2174/092986707782793862.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986707782793862</ArticleId><ArticleId IdType="pubmed">18220753</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni E., Bremang M., Mitra V., Zubiri I., Jung S., Lu C.H., Adiutori R., Lombardi V., Russell C., Koncarevic S., et al. Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis. Sci. Rep. 2019;9:4478. doi: 10.1038/s41598-019-40632-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-40632-4</ArticleId><ArticleId IdType="pmc">PMC6418138</ArticleId><ArticleId IdType="pubmed">30872628</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturmey E., Malaspina A. Blood biomarkers in ALS: Challenges, applications and novel frontiers. Acta Neurol. Scand. 2022;146:375&#x2013;388. doi: 10.1111/ane.13698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.13698</ArticleId><ArticleId IdType="pmc">PMC9828487</ArticleId><ArticleId IdType="pubmed">36156207</ArticleId></ArticleIdList></Reference><Reference><Citation>Kueffner R., Zach N., Bronfeld M., Norel R., Atassi N., Balagurusamy V., Di Camillo B., Chio A., Cudkowicz M., Dillenberger D., et al. Stratification of amyotrophic lateral sclerosis patients: A crowdsourcing approach. Sci. Rep. 2019;9:690. doi: 10.1038/s41598-018-36873-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-36873-4</ArticleId><ArticleId IdType="pmc">PMC6345935</ArticleId><ArticleId IdType="pubmed">30679616</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y.S., Lee M.Y., David A.E., Park Y.S. Nanoparticles for gene delivery: Therapeutic and toxic effects. Mol. Cell. Toxicol. 2014;10:1&#x2013;8. doi: 10.1007/s13273-014-0001-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13273-014-0001-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Lejman J., Panuciak K., Nowicka E., Mastalerczyk A., Wojciechowska K., Lejman M. Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives. Int. J. Mol. Sci. 2023;24:11301130. doi: 10.3390/ijms24021130.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24021130</ArticleId><ArticleId IdType="pmc">PMC9860634</ArticleId><ArticleId IdType="pubmed">36674643</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Cudkowicz M.E., Genge A., Shaw P.J., Sobue G., Bucelli R.C., Chi&#xf2; A., Van Damme P., Ludolph A.C., Glass J.D., et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New Engl. J. Med. 2022;387:1099&#x2013;1110. doi: 10.1056/NEJMoa2204705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Bucelli R.C., Andrews J.A., Otto M., Farahany N.A., Harrington E.A., Chen W., Mitchell A.A., et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: The ATLAS Study. Neurotherapeutics. 2022;19:1248&#x2013;1258. doi: 10.1007/s13311-022-01237-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01237-4</ArticleId><ArticleId IdType="pmc">PMC9587202</ArticleId><ArticleId IdType="pubmed">35585374</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Dodart J.-C., Tran H., Berkovitch S., Braun M., Byrne M., Durbin A.F., Hu X.S., Iwamoto N., Jang H.G., et al. Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models. Nat. Commun. 2021;12:847. doi: 10.1038/s41467-021-21112-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21112-8</ArticleId><ArticleId IdType="pmc">PMC7870851</ArticleId><ArticleId IdType="pubmed">33558503</ArticleId></ArticleIdList></Reference><Reference><Citation>Smukowski S.N., Maioli H., Latimer C.S., Bird T.D., Jayadev S., Valdmanis P.N. Progress in Amyotrophic Lateral Sclerosis Gene Discovery: Reflecting on Classic Approaches and Leveraging Emerging Technologies. Neurol. Genet. 2022;8:e669. doi: 10.1212/NXG.0000000000000669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000669</ArticleId><ArticleId IdType="pmc">PMC9128037</ArticleId><ArticleId IdType="pubmed">35620141</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold C. Custom therapies pose huge financial burdens. Nat. Med. 2019 doi: 10.1038/d41591-019-00021-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41591-019-00021-w</ArticleId><ArticleId IdType="pubmed">33110271</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L., Todeasa S.H., Cabrera G.T., Salameh J.S., ElMallah M.K., Mueller C., Brown R.H., Jr., Sena-Esteves M. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann. Neurol. 2016;79:687&#x2013;700. doi: 10.1002/ana.24618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24618</ArticleId><ArticleId IdType="pmc">PMC5374859</ArticleId><ArticleId IdType="pubmed">26891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C., Berry J.D., McKenna-Yasek D.M., Gernoux G., Owegi M.A., Pothier L.M., Douthwright C.L., Gelevski D., Luppino S.D., Blackwood M., et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N. Engl. J. Med. 2020;383:151&#x2013;158. doi: 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T., Je G., Pacut P., Keyhanian K., Gao J., Ghasemi M. Gene Therapy in Amyotrophic Lateral Sclerosis. Cells. 2022;11:2066. doi: 10.3390/cells11132066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11132066</ArticleId><ArticleId IdType="pmc">PMC9265980</ArticleId><ArticleId IdType="pubmed">35805149</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R., Liefhebber J.M., Garcia-Osta A., Miniarikova J., Cuadrado-Tejedor M., Espelosin M., Ursua S., Petry H., van Deventer S.J., Evers M.M., et al. Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Mol. Ther. Nucleic Acids. 2019;16:26&#x2013;37. doi: 10.1016/j.omtn.2019.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.02.001</ArticleId><ArticleId IdType="pmc">PMC6393708</ArticleId><ArticleId IdType="pubmed">30825670</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R., Liefhebber J.M., Miniarikova J., van der Zon T., Snapper J., Kolder I., Petry H., van Deventer S.J., Evers M.M., Konstantinova P. Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol. Ther. Nucleic Acids. 2019;14:593&#x2013;608. doi: 10.1016/j.omtn.2019.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.01.010</ArticleId><ArticleId IdType="pmc">PMC6378669</ArticleId><ArticleId IdType="pubmed">30776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J. Presymptomatic studies in ALS: Rationale, challenges, and approach. Neurology. 2012;79:1732&#x2013;1739. doi: 10.1212/WNL.0b013e31826e9b1d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31826e9b1d</ArticleId><ArticleId IdType="pmc">PMC3468777</ArticleId><ArticleId IdType="pubmed">23071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Turner M.R., Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2019;20:303&#x2013;309. doi: 10.1080/21678421.2019.1587634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587634</ArticleId><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P., Lumbroso S., Cazeneuve C., Mouzat K., Camu W., Vourc&#x2019;h P., on Behalf the FILSLAN network Pre-symptomatic diagnosis in ALS. Rev. Neurol. 2020;176:166&#x2013;169. doi: 10.1016/j.neurol.2019.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2019.07.027</ArticleId><ArticleId IdType="pubmed">31932031</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., McHutchison C., Postuma R.B., Boeve B.F., Petersen R., A Ross C., Rosen H., Arias J.J., Fradette S., et al. Preventing amyotrophic lateral sclerosis: Insights from pre-symptomatic neurodegenerative diseases. Brain. 2022;145:27&#x2013;44. doi: 10.1093/brain/awab404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab404</ArticleId><ArticleId IdType="pmc">PMC8967095</ArticleId><ArticleId IdType="pubmed">34677606</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>